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Abstract 
The optimal treatment for patients with stable angina remains controversial. Coronary angioplasty 
is increasingly performed in stable patients to reduce symptoms. Over the last 20 years there has 
been an accumulation of data demonstrating that an objective physiological approach to 
revasularisation is superior to the tradional angiographic approach.  
Several intra-coronary indices of stenosis severity have been proposed using pressure alone, 
flow velocity alone or a combination of both pressure and flow velocity. The most clinically used 
index, Fractional Flow Reserve (FFR) uses pressure alone to estimate the effect of a stenosis on 
blood flow within the coronary artery. Potent vasodilators are administered during its 
measurement to ensure the intra-coronary conditions are suitable for pressure to be used as a 
surrogate for flow. Despite the wealth of evidence supporting its use to guide coronary 
resvascularisation its adoption is poor. One reason is the need for the potent vasodilators that 
add time and cost to the procedure, cannot be given to every patient, are associated with side 
effects and in some regions of the world are simply unavailable.  
In this series of studies I will use combined pressure and flow velocity measurements to analyse 
the phasic relations of pressure and flow velocity distal to coronary stenoses. I aim to identify a 
period in the cardiac cycle that naturally provides the requisite intra-coronary condition for a 
pressure only index of stenosis severity - stable intra-coronary microvascular resistance. I will 
then compare the index derived over this period to existing pressure only and flow based indices 
of stenosis severity. Finally I will perform a detailed analysis of diastole to detemonstrate why this 
period is suitable by relating wave-mechanics to traditional pressure and flow mechanics.  
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1. Introduction 
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1.1 Ischaemic Heart Disease 
Ischaemic heart disease remains the leading cause of mortality and morbidity in the world 
(1). To combat this several treatment options are available for patients and the physicians 
treating them. These vary from non-invasive (medication, life style modification) to invasive 
therapy (coronary angioplasty, coronary artery bypass grafting). Since the first balloon 
angioplasty in 1977 by Andreas Gruentzig (2), the use of coronary angioplasty has grown 
rapidly. This has been aided by the introduction of intravascular coronary stents (3). 
 
Often these patients have more than one stenosis in one or more of their coronary arteries 
and determining which lesion is causing the patient’s symptoms is difficult for the physician.  
As a result a proportion of these patients have non-invasive stress tests to try and guide the 
interventional cardiologist towards the culprit stenosis. Unfortunately these tests have their 
limitations (particularly in multi-vessel disease) and can only isolate ‘ischemia’ to the level of 
a myocardial territory that may be supplied by several vessels each with a varying degree of 
disease (4). Furthermore only a small proportion of patients being referred for invasive 
assessment actually have a non-invasive test prior to arrival in the catheterization laboratory.  
 
This has lead to the development of invasive measures of coronary stenosis severity which 
use pressure (4), flow or both to determine stenosis severity (6). Intra-coronary pressure was 
originally described as a possible tool for interventional cardiologists by Andreas Gruentzig 
himself in 1979. However, the clinical utility of such information has only really been explored 
over the last 20 years with improvement of intra-coronary wire and pressure transducer 
technology.  The premise of such intracoronary indices is to determine the effect of the 
stenosis on coronary hemodynamics. An appreciation of the physiological basis of these 
indices therefore requires an understanding of interplay between the contracting and 
relaxing myocardium and coronary blood flow.  
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1.2 Interplay between intracoronary blood flow and the dynamic myocardium 
In all arteries blood flow occurs in the presence of a pressure gradient. In systemic arteries 
this pressure gradient is usually generated at the proximal (aortic) end of the vessel, driving 
blood towards the capillary bed. The coronary circulation however provides an exception, 
where fluctuations in pressure not only originate at the proximal end of the vessel, but also 
originate from the distal (microcirculatory) end of the vessel (7-9).  These distal-originating 
pressure changes are actively generated by compression and decompression of the 
microvasculature, which cause the flow velocity waveform in the coronary artery to be very 
different from that of a systemic artery such as the aorta (Figure 1.01).  
 
The effect of the contracting myocardium on blood flow was first demonstrated in an 
instrumented canine model by Spaan et al. (10). In a series of elegant studies it was 
demonstrated that as perfusion pressure to the coronary artery was reduced, a critical 
pressure was reached below which blood flow reversed in a pulsating fashion – indicating a 
dynamic source of pressure generation from the myocardial bed. In practice the influence of 
the myocardium on coronary hemodynamics is evident by simply inspecting the pressure 
and flow velocity wave-forms at different times of the cardiac cycle (Figure 1.01). For 
example during diastole it can be seen that flow velocity increases rapidly whilst intra-
coronary pressure falls.  Such a combination of falling pressure and increasing blood flow 
would not fit the haemodynamic model of a systemic vessel that has a single proximal input 
of pressure. However, it is possible, and indeed normal, in a scenario in which pressure also 
originates from the distal circulation as occurs in the coronary arteries. The acceleration in 
blood flow during this period in the face of falling pressure can therefore only be due to a 
suction effect originating from the distal vessel, which accelerates blood flow into the 
microcirculation. Wave intensity analysis is an investigational tool, pioneered by Prof Kim 
Parker, that combines information from dynamic changes in pressure and flow velocity to 
quantify such effects of the dynamic myocardium on blood flow as ‘waves’.  
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1.3 What is wave intensity analysis? 
A wave is defined as a disturbance that propagates from one place to another with time.   
Wave intensity analysis can be used to identify and quantify these waves and in its simplest 
form, net wave intensity, it is calculated as the product of the change in pressure (dP) and 
change in flow velocity (dU) at a particular point in the cardiac cycle. Its units are of power 
(Ws-2m-2); with a negative value indicating a backward-travelling wave and a positive value a 
forward-travelling wave. In the context of coronary arteries, backward-travelling waves 
originate from the microcirculatory or distal end of the vessel, and forward-travelling waves 
from the proximal end of the vessel (Figure 1.02) (8, 9).  Originally used to study gas 
dynamics, the ability of wave intensity to quantify and separate waves according to their 
origin and direction of propagation make it an ideal tool to study the coronary circulation; 
which has pressure perturbations originating from both the proximal and distal ends. By 
identifying and quantifying the origin of these waves throughout the cardiac cycle the 
predominant determinant of coronary flow at any given point in the cardiac cycle can be 
determined (Figure 1.02).  
 
The derivation of waves, estimation of wave speed and techniques for measurements and 
calculation of net and separated wave-intensity analysis have been extensively described  
by Prof Kim Parker (7-9, 11). The principle equations for the calculation of coronary artery 
wave-intensity are highlighted below.  
 
Proximal originating wave intensity: 
 
 
Distal originating wave-intensity:  
 
 
Net wave-intensity: 
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Where ρ is the density of blood, c wave-speed, dU change in flow velocity and dP change in 
pressure. 
 
1.4 Principal assumptions and requirements of wave-intensity analysis 
Each wave is a product of changes in pressure and flow velocity at any individual time point 
in the cardiac cycle.  It is therefore important to ensure high quality pressure and flow 
velocity envelopes are obtained when measurements are taken to ensure the subsequent 
derivation of wave-intensity is an accurate reflection of underlying phasic coronary 
hemodynamics. Whilst achieving a high fidelity flow wave envelope can be time consuming it 
is usually obtainable by operators experienced in flow velocity measurements and is aided 
by the use of a combined pressure and Doppler tipped wires that enable simultaneous 
capture of pressure and flow velocity.   
 
The main assumption in the derivation of wave intensity itself lies with the use of the single 
point measure of local wave-speed (11). An initial pre-requisite for the use of wave-intensity 
in the coronary circulation was the development of a new means of estimating wave-speed 
when making measurements of pressure and flow velocity at only a single point in the 
coronary artery.  Using the relationship between simultaneous pressure and velocity and the 
density of blood as a constant, a new equation was derived to estimate local wave speed 
(Equation 2).  Whilst initial validation work involved assessment of this in the aorta it is 
applicable in any artery in which simultaneous measure of pressure and velocity can be 
made, and is correct when taken over at least one complete cardiac cycle.  
 
Equation for single point estimate for wave-speed (c): 
 
 
1.5 Wave-intensity and current clinically used indices 
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Wave-intensity has been used to delineate coronary hemodynamics in several pathological 
conditions such as left ventricular hypertrophy, aortic stenosis and congestive cardiac failure. 
However, it has not been used to assess hemodynamics in coronary stenoses. Current 
clinically used indices measure pressure, flow or a combination of both to assess stenosis 
severity. However, pressure distal to a coronary artery stenosis does not simply reflect the 
severity of the stenosis but is a composite of residual proximal pressure and pressure arising 
from the contraction and relaxation of the myocardium distally. This relative contribution of 
proximal and distal influences on intra-coronary pressure and flow cannot be appreciated by 
simply measuring either pressure or flow alone. As a result intra-coronary pressure, trans-
stenotic pressure gradients and flow velocity at specific periods of the cardiac cycle can 
poorly reflect the hemodynamic significance of a stenosis.  
 
This was first highlighted by a series of experiments by Gould (12) in the canine model in 
which varying degrees of coronary stenosis were assessed using pressure and flow velocity 
both at rest and during adenosine administration. He demonstrated that intra-coronary 
pressure distal to a stenosis was indeed confounded by the effect of contraction and 
relaxation of the myocardium. This resulted in stenosis severity being under estimated 
(during systole) or over estimated (during early diastole) depending on the point in the 
cardiac cycle during which assessment was made. In this study he concluded that there was 
a period in the cardiac cycle ‘free of accelerative and decelerative forces’ during which intra-
coronary pressure and flow velocity were most reflective of the up stream stenosis. During 
this period he demonstrated that the transtenotic pressure gradient had a quadratic 
relationship with flow velocity, ΔP=Fv+SV2; with frictional (F) and separation (S) co-efficients. 
Identification of this period required measurement of pressure and flow using two separate 
wires consecutively and then post hoc analysis of the data to accurately identify the most 
appropriate period of the cardiac cycle. This limited the clinical use of such a window for 
stenosis assessment. Furthermore, whilst the findings of Gould are widely accepted, until 
recently phasic real time analysis of the cardiac cycle has not been possible. As a result 
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despite being derived after the findings of Gould the main clinically used coronary 
physiologic indices of stenosis severity have traditionally used whole cycle measurements. 
By using modern pressure sensor technology and using wires that can enable combined 
pressure and flow velocity measurements wave intensity provides a unique tool to assess 
the phasic behaviour of pressure and flow and how this varies according to stenosis severity 
in real time; providing the possibility of new insights into the hemodynamics of diseased 
coronary arteries.   
 
1.6 Fractional Flow Reserve 
Fractional flow reserve is calculated as a ratio of distal to proximal pressure across a 
stenosis. This ratio has been demonstrated to correlate with the ratio of flow in a stenosed 
artery to flow in the same unobstructed artery. It relies on the principle of Ohm’s Law which 
states that the trans-stenotic pressure ratio is proportional to flow velocity when 
microvascular resistance is constant. During the derivation of this index the investigators 
demonstrated that when microvascular resistance is constant the reduction in pressure distal 
to a stenosis is strongly correlated to the reduction in flow (5, 13). 
 
Whilst it is commonly assumed that microvascular resistance must be minimal to ensure a 
proportional relationship between pressure and flow, Ohm law demonstrates that this is not 
true – for pressure to be used as a surrogate for flow, microvascular resistance simply needs 
to be constant. In order to obtain ‘constant’ microvascular resistance fractional flow reserve 
is required to be calculated under conditions of hyperaemia. Originally this involved the 
administration of papaverine using the rationale that if microvascular resistance can be kept 
minimal it is also constant. The minimisation of microvascular resistance was therefore used 
to limit variability.  
 
Due to a risk of prolonged QT interval induced by papavarine the vasodilator of choice was 
switched to adenosine. Over subsequent years the use of fractional flow reserve has been 
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systematically evaluated as a tool for the guidance of revascularisation in clinical practice. 
Having demonstrated it was safe to defer therapy on the basis of a FFR>0.75, the 
investigators then went on to demonstrate that it was safe to guide revascularisation 
according to a FFR treatment threshold. The FAME and FAME II studies demonstrated that 
treatment of lesions with a FFR value less than 0.8 and deferral of treatment of stenosis 
greater than this value is associated with improved clinical outcomes and reduced 
healthcare costs (14-17).  
 
Based on the wealth of clinical data the use of FFR to guide revascularisation has a 1A 
recommendation in clinical guidelines.  
 
1.7 Flow velocity, Volumetric flow and Flow based indices 
Flow velocity is used as an estimate of volumetric flow in intra-coronary physiological 
studies. One of the limitations of this is that for a given rate of flow along a vessel, velocities 
can vary both along the direction of flow, for example due to changes of diameter or other 
irregularities of contour, and across the direction of flow as a result of different spatial 
‘profiles’ of velocities across the lumen. It is therefore necessary that such mesurements are 
meticulously made to ensure that the optimal flow velocity envelope is obtained. This has 
limited the use of flow velocity indicies in general clinical practice.  
 
There are several flow velocity based measurements of coronary hemodynamics. They vary 
according to their use of simultaneous pressure measurements and epicardial to 
microvascular specificity. The indices referred to in this thesis are described below. 
 
1.7.1 Coronary Flow Reserve 
One of the first measures of stenosis severity, coronary flow reserve is defined as the ratio of 
basal to hyperaemic flow in a coronary artery. The ratio is a reflection of the ability of the 
coronary artery to increase flow – termed the vessel’s vasodilator reserve. Uren et al. (18) 
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demonstrated that the ability of a vessel to increase flow is reliant on basal vasomotor tone. 
A greater basal tone reflected a more constricted the microvasculature and resulted in a 
greater the vasodilator reserve. This was most elegantly demonstrated in diseased coronary 
arteries where vasodilator reserve was shown to have an inverse relationship to epicardial 
stenosis severity. 
 
A key limitation of CFR is its inability to differentiate epicardial and microvascular resistance 
and its relatively greater sensitivity to variations in perfusion pressure. As a result its use as 
a means of assessing epicardial severity has been superseded by more epicardial specific 
indices. 
 
1.7.2 Hyperaemic stenosis resistance index (HSR) 
Derived and validated around the same time as fractional flow reserve (FFR) this index is 
based on simultaneous measurement of trans-stenotic pressure gradient and distal flow 
velocity. HSR has the advantage of indexing the change in pressure across a stenosis with 
the change in coronary flow (19-22). It is therefore able to give a more specific measure of 
stenosis resistance rather than simply measuring flow or pressure alone. HSR has 
consistently been demonstrated to be more specific for the detection of stenosis induced 
ischemia when compared to CFR and FFR. However its adoption into clinical practice has 
been limited due to the challenges of measuring flow velocity. 
 
1.7.3 Hyperaemic microvascular resistance 
This index provides a measure of microvascular resistance and is calculated as the ratio of 
distal pressure to distal flow velocity (23-24). The ratio of basal microvascular resistance to 
hyperaemic microvascular resistance therefore represents a measure of the ability of the 
microvasculature to vasodilate and lower resistance. In effect it is another means of 
determining vasodilator reserve. The measurement of pressure ensures that the increase in 
flow is indexed per mmHg of pressure. Therefore values can be more readily compared 
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between individual with different perfusion pressures. As a result it is a more favoured 
means of determining flow reserve than CFR.  
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1. 8 Aims of this thesis 
Despite a variety of intra-coronary indices their clinical adoption to guide revascularisation is 
low. One of the reasons for this is the need to administer adenosine. This adds cost and time 
to the procedure, whilst in some countries its cost is prohibitive or it is simply not available; 
furthermore patients often suffer discomfort during adenosine administration. The use of 
adenosine has a dual purpose in physiologic assessment. In pressure derived indices it is 
required to induce stable microvascular resistance whilst also unmasking trans-stenotic 
pressure gradients that were difficult to detect with the poor fidelity pressure wires available 
during its derivation, which only permitted cycle averaged measurements. In the pressure 
and flow derived index of HSR adenosine is simply used to increase flow velocity to unmask 
pressure gradients. However, pressure wire fidelity has improved significantly since the 
derivation of FFR and HSR. The overall aim of this thesis, therefore, is to determine if 
adenosine is still required for stenosis assessment using current high fidelity pressure and 
flow wires that permit real-time phasic analysis of the cardiac cycle.   
 
Wave-intensity analysis has demonstrated that hemodynamics vary considerably within each 
cardiac cycle. How such variations effect stenosis assessment has not previously been 
explored. In the following series of studies I first use wave intensity analysis to characterise 
the effect of the dynamic myocardium on blood flow distal to coronary stenoses to determine 
if there is a period in the cardiac cycle most suitable for stenosis assessment. I subsequently 
aim to derive a new index of stenosis severity that can be calculated under basal conditions. 
Finally, I use pressure and flow velocity to ascertain why a basal index could provide similar 
physiologic information as adenosine based indices. 
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2. Materials and Methods 
 30 
2.1 Pre-assessment 
Participants were identified from the Imperial College NHS Trust angiography and 
angioplasty waiting list. These were patients that were listed for angiography and 
percutaneous coronary intervention for clinical reasons and at no point inclusion to the 
research study influenced decision-making. Patients eligible for a particular study were 
offered a pre-assessment appointment one week prior to their scheduled procedure. 
At pre-assessment, patients were informed about the procedure they were scheduled to 
have and also invited to participate in the research study. Information was given with regard 
to the research study (Appendix I). On the day of their procedure if the patient was willing to 
participate in the study, a study consent form was completed (Appendix I). All studies were 
approved by the local research committee (NRES ref: 09/H0712/102; NCT01118481). 
 
2.2 Investigations 
2.2.1 Electrocardiogram 
An electrocardiogram (ECG) was recorded for each subject throughout each study, using a 
LifePulse MMC (model number LP10). The position of each electrode was adjusted to 
ensure that the R wave was positive and was the dominant deflection. The ECG console 
outputted a continuous ECG wave signal from which was fed to the analogue input port, as 
discussed later. 
 
2.2.3 ComboMap system (model 6800) 
The ComboMap system (Figure 2.01) processes the information it receives from the guide 
wire (ComboWire), pressure transducer (from the catheter table) and other external inputs. 
Intravascular blood pressure and/or blood flow velocity measured in the coronary and/or 
peripheral arteries during diagnostic and/or interventional procedures are displayed on the 
console screen in real time (Figure 2.02). 
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2.2.4 The ComboWire XT  
The ComboWire is a steerable guide wire which combines two different sensors. The guide 
wire has a diameter of 0.014" (0.36 mm) and a length of 185 cm (Figure 2.03). The CombTip 
type (model reference 9500) that was used in this study contains a pressure transducer and 
an ultrasound transducer, both mounted in a single housing at the tip of the guide wire. The 
ComboWire was connected to the ComboMap system via the patient interface module which 
conveyed the signals of Doppler flow velocity and pressure from the wire to the console. 
 
2.2.5 Same point measurements 
Wave intensity analysis requires that the point of acquisition of both pressure and flow is the 
same and, ideally synchronous. Whilst both the pressure and Doppler sensors are close to 
the tip in the ComboWire, there remains a difference of 5mm in distance between the two 
sensors because it is not possible to place the sensors in exactly the same position. It is 
extremely unlikely that there would be a significant degree of impedance mismatching over 
such as short distance so a spatial displacement of this magnitude can be regarded as 
effectively the ‘same point’. In theory this displacement will also introduce a time delay 
between the pressure and velocity signals. The degree of this delay depends on the wave 
speed. For wave speeds between 5 - 60 m/s which correspond to the range in arteries at 
rest and during hyperaemia the delay can be calculated to be between 0.25 – 1 ms (delay = 
distance / wave speed). Given that the sampling rate of the Doppler signal is 100Hz this 
delay was considered negligible and was not corrected for. 
 
2.2.6 Pressure sensor 
The pressure sensor uses the MEMS (MicroElectroMechanicalSystems) technology to form 
a thin silicon diaphragm over a reference pressure chamber. Tiny resistors are embedded in 
the diaphragm, and their resistances change when the diaphragm flexes in response to the 
changing blood pressure. The pressure electronics monitors the resistor values, using 
factory calibration coefficients to convert the resistance into a pressure reading. 
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2.2.7 Doppler sensor 
The Doppler sensor uses quartz crystals (piezoelectric crystals). When an electric current is 
applied to these crystals, they change shape rapidly. The rapid shape changes, or 
vibrations, of the crystals produce sound waves that travel outward. Conversely, when sound 
or pressure waves hit the crystals, they emit electrical currents. Therefore, the same crystals 
can be used to send and receive sound waves. Thus the piezoelectric transducer can be 
used both to transmit and receive ultrasound signals. The signal processing electronics uses 
the pulsed-wave Doppler method, generating the transmit burst waveforms and processing 
the frequency-shifted echo signals to extract the blood flow velocity information from the 
received signal (Figure 2.04). 
 
2.2.8 Calculation of pressure-velocity signal delay 
For accurate determination of wave intensity analysis it was vital that measurements of 
pressure and velocity were correctly aligned in time. While sensor displacements introduce 
only trivial relative delays in signals, there are processing delays in the ComboMap which 
differ for each of the pressure and Doppler sensors. Previous bench top studies have 
demonstrated this delay to be 43ms (mean 42.5±3.8ms) (7, 11). This delay was subtracted 
from the timing of the pressure data in all subsequent analyses, so that both pressure and 
Doppler signals were synchronous. 
 
2.2.9 Combo mode 
We used the Combo mode on the console screen (as displayed in Figure 2.02) to display 
both pressure and Doppler signals. In this mode, both pressure and Doppler scales were 
adjusted to optimize the display of the signals accordingly. 
 
2.2.9.1 ECG input 
Real time signals of pressure and Doppler velocity can also be outputted via the connector 
panel which is situated at the back of the ComboMap (Figure 2.05). Via this connector, we 
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connected the patient’s ECG signal to display it as a scrolling waveform on the monitor 
(Figure 2.06). 
 
2.2.9.2 Pressure input 
The ‘Aortic/Aux 1 in’ high level input was used to feed aortic pressure recorded via the guide 
catheter into the console. This was necessary for the calculation of the various intra-
coronary indices which require simultaneous aortic pressure measurements for their 
calculation (Figure 2.06). 
 
2.2.9.3 Pressure output 
The high level output of the ComboMap system (Aortic/Aux 1 out and Distal/Aux 2 out) was 
used for outputting the pressure signals. Aortic out is the aortic signal recorded by the guide 
catheter during the procedure (Pa). The distal signal is the distal pressure (Pd) recorded 
from the ComboWire.  This output gave 1volt for every 100mmHg. 
 
2.2.9.4 Doppler flow output 
To output the instantaneous peak velocity (IPV) and average peak velocity (APV) signals 
from the Doppler measurements, the high level APV/Q and IPV/I connections were used 
respectively (Figure 2.06). 
 
2.3 Acquisition system design 
2.3.1 Hardware 
The outputted signals of pressure and velocity taken from the ComboMap connector panel 
were in analogue form. These signals together with the electrocardiogram signal were fed 
into a BNC connector box (BNC-2010, National Instruments). A 70 multi-pin output cable 
was then fed from this connector box into a National Instruments analogue to a digital 
PCMCIA card (DAQ-Card AI-16E-4) within the PC (Figure 2.07). 
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2.3.2 Software 
Customized data acquisition software was developed and written using Labview (National 
Instruments). The hardware and software was developed to be stable at high sampling 
frequencies (in excess of 10000Hz). However, as the output frequency from the ComboMap 
console was substantially lower, the sampling frequency was standardized at 1000Hz. Each 
of Pa, Pd, IPV, APV and ECG were stored in an .SDY file. This was exported at the end of 
the procedure and analysed in customised software programme that allowed conversation of 
the data into text files for analysis in Matlab.  
 
2.3.3 Post-acquisition Signal Processing 
After acquisition, signal processing and data analysis were performed using customized 
software written in Matlab. This software was fully-automated to allow 100% reproducibility in 
the measurement of haemodynamic data and calculation of wave intensity analysis.  
 
2.3.4 Filtering 
All data was passed through a Savitzky-Golay smoothing filter. This filter is ideal for 
smoothing haemodynamic signals whose frequency span (without noise) is large. This is 
typical of haemodynamic data where it is common for peaks and troughs to occur rapidly in 
succession within a short time period. The Savitzky-Golay filter fits a polynomial to each 
frame of data to minimize the least of squares error. It is thus more effective at preserving 
pertinent high frequency components of a signal than standard averaging filters. However, 
whilst the Savitzky-Golay is very good at preserving high frequency components, it is less 
good than standard averaging filters at removing noise. Savitzky-Golay polynomial order and 
frame width constants were set at 3 and 31 respectively in all data analysis. 
 
2.3.5 Ensemble averaging 
All haemodynamic recordings made were at least 60 seconds in duration. However, to 
analyze wave intensity a single representative waveform is required. To do that, we 
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ensemble averaged the recorded data. The advantages of ensembling are that any random 
noise is removed in the averaging process. The disadvantages are that it relies on precise 
determination of the fiducial point. If this is not correct, ensembled pressures and velocity 
traces become distorted with a loss of fine detail and a blunting of the peaks and troughs. 
 
2.3.6 The fiducial point for the data ensemble 
A series of post-processing tests were undertaken to identify the best fiducial (reference) 
point for data ensembling. Fiducial points were identified using fully-automated custom 
written algorithms in Matlab. After selection of the fiducial points, data was ensembled and 
the accuracy of these automated algorithms assessed by inspection of the ensemble traces. 
The best and most reliable fiducial point was found to be the R wave of the ECG. This was 
used in all data analysis. 
 
2.3.7 Recording of the study 
The ‘real time’ traces of pressure, Doppler and ECG displayed on the ComboMap screen 
were saved onto the ComboMap hard drive and backed up with a CD (Figure 2.07). This 
enabled us to play the whole study again at a later stage for further analysis of the signals if 
needed. 
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2.4 Set-up in the catheterization laboratory  
2.4.1 Catheters 
To standardize the procedure, all recordings were made via a 6 French guiding catheter. It is 
standard clinical practice to use guide catheters during the physiologic assessment of 
stenoses because they offer better inner coating, have a larger lumen and allow better 
torque control of the wire by the operator.  
 
2.4.2 Medication 
Since most patients studied were being investigated for possible coronary artery disease, it 
was deemed unethical to stop any of the medications they were taking prior to the 
procedure. Before the insertion of any intracoronary wire, 5000IU of heparin was given 
intravenously to reduce the risk of thrombosis. Furthermore, the activated clotting time (ACT) 
was measured at regular intervals and maintained above 250 seconds. Intracoronary GTN 
(300mcg) was administered to each artery before physiological assessment was performed 
to ensure no epicardial artery spasm. 
 
2.4.3 Induction of hyperaemia  
Current clinically used indices of coronary stenosis and microvascular resistance are 
measured during the administration of adenosine. The clinically recommended dose varies 
according to its route of administration. Intravenously a dose of 140mcg/Kg/min of adenosine 
via femoral venous line is recommended; intra-coronary a dose of up to 120mcg of 
adenosine by rapid bolus injection directly into the target vessel. Only an intravenous route 
of adenosine administration was used when simultaneous pressure and flow velocity 
measurements were made. This was done to ensure adequate time was available to achieve 
the best possible flow velocity envelope which is especially challenging in vessels with 
severe stenoses. 
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2.4.4 Pressure measurement 
2.4.4.1 Aortic pressure measurement 
We used fluid-filled hollow guide catheters to measure aortic pressure (Pa) throughout the 
procedure. Pressure is transmitted through a tiny fluid column to an external pressure 
transducer, to which the fluid-filled system is connected. In order to maintain the highest 
level of quality of the pressure trace, the distance between the coronary artery to the 
pressure transducer was kept to the minimum and the catheter was kept free of bubbles. 
The pressure transducer was fixed to the catheter table to avoid erroneous readings of 
pressure due to height changes of the transducer. Before use, each of the fluid-filled 
catheters was zeroed at the right atrial level with the patient supine.  
 
The pressure waveform was displayed continuously on a screen to be viewed by the 
operator together with minimum, maximum and mean values of aortic pressure. The 
standard procedure in the catheterization laboratory is to mount the pressure transducer of 
the guiding catheter at a height of 5 cm below the sternum, which is estimated to be the 
location of the aortic root. As this is merely estimation and can be incorrect, pressure 
readings may be also be incorrect. Therefore, by adjusting the height of the pressure 
transducer small errors in pressure can be corrected; decreasing the level of the transducer 
increases aortic pressure, increasing the height of the transducer will decrease aortic 
pressure. This manoeuvre was only carried out if during the verification process of 
comparing the fluid-filled pressure reading with that of the guide wire (at the time when the 
guide wire is positioned at the tip of the guide catheter while sitting at the coronary ostium) 
there was a pressure difference between the two readings. This step is explained on the 
section on equalizing pressure. 
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2.4.4.2 Pressure-monitoring guide wire 
The ComboWire XT 0.0 guide wire (Volcano therapeutics) was used to measure coronary 
pressure (Pd) and a new sterile wire was used for each patient. Calibration of the pressure 
wire was carried out outside the body, with the wire positioned and rested on the table, 
through an automated process by the ComboMap. Once this was done, the ‘ready’ signal 
displayed on the touch screen enabled use of the wire. At baseline and with the wire outside 
the body, a check was carried out to ensure that Pd was reading zero pressure. If not, the 
wire was zeroed. Only then, was the wire removed from the spiral. Furthermore, to help with 
rotational movements and manipulation in the coronary arteries, the shapeable guide wire tip 
was carefully shaped using standard tip shaping practices. With experience, we found that 
for best results, the shaping of the tip had to be done in the direction of the sensor housing 
opening. Under fluoroscopic imaging, the wire was positioned in the coronary artery at the 
site of interest and on occasions torque was applied to facilitate this. 
 
2.4.4.3 Equalising pressure in the ascending aorta 
At the coronary ostium, the pressure displayed by both the fluid-filled system and the 
pressure wire were compared. At this point to ensure wire pressure was equal to aortic 
pressure the wire pressure was equalised to aortic pressure. The next step of the protocol 
was only followed once it was confirmed that there was no difference in the two pressures. A 
guide wire introducer was placed in the Y-connector to facilitate wire manipulations in the 
coronary artery. The space around the wire within the introducer may leak and lead to aortic 
pressure measurements which are below the actual pressure. Although in every case we 
checked that the introducer was not leaking, we took the extra precaution of making all 
measurements with the introducer out and the Y-connector always locked in the closed 
position so that there was no leakage around the wire. 
 
It should be noted that equalisation of pressure occurred in the aorta and therefore in the 
presence of a clear dicrotic notch on the pressure wave form. The presence of this notch 
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was ensured throughout the measurement process to ensure no damping of aortic pressure 
was present which has been shown to result in inaccurate intra-coronary measurements. 
Such a damped trace provides a lower aortic pressure than is actually present. This can lead 
to artificially high pressure ratios.  
 
2.4.4.4 Signal drifting 
One problem encountered during some of the procedures was signal drifting. This is a 
phenomenon which is frequently encountered during pressure wire measurements and a 
drift of <5mmHg per hour has been previously regarded as acceptable (25). However, due to 
the magnitude of the measurements we were making we refused to accept any drift in the 
measurements. As a result after each of the measurements the pressure sensor was 
returned to its original position in the aorta (where equalisation was performed) to ensure 
there was no drift. If any drift was detected the measurements were repeated. If the wire 
continued to drift it was replaced. No post hoc correction of drift was therefore necessary.  
 
2.4.4.5 Flow velocity measurement 
The ComboWire XT 0.0 guide wire (Volcano therapeutics) was used to measure 
instantaneous peak velocity of blood (IPV) simultaneously with Pd. A new sterile wire was 
used for each patient. Doppler velocity is measured approximately 5 mm from the tip of the 
wire. The pulsed Doppler beam angle is 45 degrees and insonates a sample volume of 
approximately 4 mm downstream of the Doppler probe. Fine rotational movements were 
carried out so that the Doppler beam captured the highest velocity. The intensity of the 
Doppler envelope was taken as indicative of this (Figure 2.08). Acquisition of the Doppler 
signal proved the most demanding aspect of the study acquisition process. With experience 
we were able to get a strong, dense and steady signal even in the most challenging cases.  
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2.5 Calibration before each study 
2.5.1 Pressure calibration 
2.5.2 Input calibration 
The two sources of pressure in the ComboMap were the guide catheter and the ComboWire. 
When exposed to ambient pressure, small differences in the zero line for each of these 
pressure transducers may be present. For this reason, both pressure signals were compared 
at the zero mmHg signal. If there was a difference, it was corrected by pressing the zero 
button. 
 
2.5.3 Output calibration 
To test the output of each of the pressure signals, a calibration signal was sent to the 
acquisition computer screen via the output reference buttons. 
 
2.5.4 Doppler calibration - Doppler spectrum input 
2.5.4.1 Wall filter 
At each location, the wall filter function was used to reduce or eliminate low frequency noise 
returning in the Doppler spectrum when the transducer was near an artery wall. Available 
settings are 200, 400, 800 and 1600Hz, the optimum was found to be at 400Hz and this 
setting was used in the majority of the cases. 
 
2.5.4.2 IPV threshold 
The IPV threshold is a signal to noise ratio, and establishes the signal threshold: signals 
below this level are considered noise and not displayed or used for flow measurements. The 
IPV threshold was set by optimizing the IPV envelope which is displayed as a blue envelope 
around the flow spectrum. This was adjusted manually in all patients and all vessels studied 
to ensure that the blue tracking envelope matched the outer edge of the velocity spectrum. A 
range of 0-3 was used for the majority of studies. 
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2.5.4.3 Doppler spectrum output 
To test the output of the Doppler signal, a calibration signal was sent to the acquisition 
computer screen via the output reference buttons. Output reference was available at 
selections of 0, 100, 250 and 500cm/s. The output voltage was in the range 0-5 volts which 
implied that the output reference was scaled accordingly. For example, if a scale factor of 
100cm/s is selected, the 5-volt output covers the range of 0-100cm/sec. In this example, an 
IPV reference of 100cm/s is equivalent to 5 volts. If, however, 500cm/s is selected, the 5-volt 
range covers 0-500cm/s. In this case, an IPV reference of 100cm/s is equivalent to 1 volt. 
We have previously demonstrated that the 250cm/s scale factor maximized the amplitude of 
the Doppler signals in the majority of the cases; we therefore set this value in all of our 
studies to avoid any scaling confusion in our acquisition process. This scaling factor outputs 
1 volt for every 50cm/s measured. 
 
2.6 Reproducibility 
Reproducibility of hemodynamic measurements has been demonstrated previously (7). The 
mean and standard deviation of the difference between the separate 30-second recordings 
of blood pressure was 12.0±269 Pascal (7,11). The mean and standard deviation of the 
difference between the separate 30-second recordings of flow velocity was 0.007± 0.022 m/s 
(7,11).  
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Figure 2.05: Connector panel of the ComboMap 
Situated at the rear of the console the connector panel has low and high output 
and input connections. These enable ECG (ECG in), aortic pressure through the 
guide catheter (aortic in) to be inputted into the console system. In addition, the 
signals of all of the Doppler (IPV/I and APV/Q), aortic pressure (aortic in/aux1 in) 
and distal pressure through the ComboWire (Distal/Aux 2 Out) can be outputted 
for further offline analysis 
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3.0  The optimal period in the cardiac cycle for the assessment of a 
coronary stenosis 
 51 
3. 1 Abstract 
3 1.1 Background 
For pressure to be a physiologically and clinically valid surrogate for flow, trans-stenotic pressure must 
be proportional to flow. In this study we examine phases of the cardiac cycle to identify the most 
suitable phase for stenosis discrimination.  
3.1.2 Methods 
Pressure and flow velocity was measured in 56 vessels distal to a coronary stenosis at rest.  
Mean flow velocity, microvascular resistance, trans-stenotic pressure difference, distal to proximal 
pressure ratio and micro-vascular resistance were calculated over the complete cardiac cycle, 
and over 50 intervals within diastole. Instantaneous pressure gradient-flow velocity curves were 
constructed. 
3.1.4  Results 
Pressure gradient flow-velocity curves demonstrated two phases within diastole, which differed 
with regard to their ability to determine stenosis severity.  During the first phase the trans-stenotic 
pressure gradient lead to an over-estimate of stenosis severity. In contrast, there was a wave-free 
period occupying 75.8±8.6% of the period between the dicrotic notch and the end of diastole 
during which pressure loss due to the stenosis had a proportional relationship with flow velocity. 
The mean pressure difference during the wave-free period varied according to stenosis severity 
(4.4±4.2mmHg mild vs 13.3±12.2mmHg moderate and 55.7±11.1mmHg severe stenoses, 
p<0.001).   
3.1.5  Conclusions 
A wave-free period can be defined in diastole during which the trans-stenotic pressure 
gradient is proportional to flow velocity: the necessary condition for pressure-only 
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assessment of a coronary stenosis. These findings suggest that the requisite intra-coronary 
conditions for pressure-only stenosis assessment can be achieved without the need for 
potent vasodilators.  
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3.2  Introduction 
Purely pressure-derived indices of coronary stenosis severity, such as fractional flow reserve 
(FFR) have been reported to improve clinical outcomes when used to guide coronary 
revascularisation (14-17). Such pressure-only indices infer the effect of the stenosis on 
coronary blood flow by considering it equivalent to a resistor obeying Ohm’s law: pressure 
drop (∆𝑷) across a stenosis is proportional to flow (𝑄) if microvascular resistance (𝑹) is 
constant (Equation 1). Using this perhaps overly simplistic analogy (see below) under 
conditions of relatively constant micro-vascular resistance pressure can be used as a 
surrogate for flow4.   
 
Equation 1:  Ohm’s Law: ∆𝑷 = 𝒗𝑹 
  When resistance is constant (𝑹): ∆𝑷 ∝ 𝒗  
 
3.2.1 The capacitive effect of the coronary circulation: implications for the 
application of Ohm’s law to stenosis assessment 
 
If we assume that the flow in the stenosed coronary artery can be described as flow through 
two resisters in series; the resistance due to the stenosis Rs and the resistance due to the 
microcirculation Rc. We assume that Rs is constant but that Rc is a function of time because 
of the constriction of the microcirculatory vessels during systole. Assuming a simple Ohms 
law relationship between resistance and flow through the two resistances, ΔP=QR, where 
ΔP is the difference between the upstream and downstream pressure. For simplicity we 
further assume that the pressure in the venous system is negligible. With these 
assumptions, the instantaneous flow rate through the coronary artery Q(t) = Pa(t)/(Rs + 
Rc(t)) where Pa(t) is the time-varying pressure in the aorta. The pressure downstream of the 
stenosis but upstream of the microcirculation can then be written Pd(t) = Pa(t) - Q(t)Rs. 
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Substituting for Q(t) from the previous equation we can write (after a little algebraic 
manipulation) Pd(t)/Pa(t) = Rc(t)/(Rc(t)+Rs). 
 
This shows that the instantaneous ratio of downstream to upstream pressure will vary in time 
when Rc varies with time. If Rc is constant in time, this expression is simply Pd(t)/Pa(t) = 
Rc/(Rc+Rs) which indicates that the instantaneous ratio of pressures is constant. Further, if 
the Rs << Rc the pressure ratio can be approximated as Pd(t)/Pa(t) = 1 – Rs/Rc where the 
error of the approximation is of order (Rs/Rc)2. 
 
In the FFR method, a vasodilator is injected into the coronary artery to minimise the variation 
of Rc during the entire cardiac cycle. In the IFR method, a period during diastole is identified 
when Rc is minimal and effectively constant. 
 
The above analysis is predicated on the assumption that P and Q are related solely through 
an Ohms law resistance. In general the relationship is more complex because of the 
distensibility of the artery which introduces a capacitive effect that can be important in the 
non-steady conditions during the cardiac cycle. A simple way to test for the influence of 
capacitive effects is to plot ΔP vs Q or, because we measure velocity, v, which is related to 
Q through the cross-sectional area of the artery, ΔP vs v (the  ΔPv-loop). At times when the 
capacitive effects are negligible the ΔPv-loop should have a linear relationship with slope Rs. 
When capacitive effects are important, the ΔPv-loop will not be linear, depending on the 
unsteady nature of the flow. Similarly, more detailed fluid dynamic analysis of steady flow 
through stenosis suggests that the pressure drop across the stenosis can be written in the 
approximate form ΔP = Fv + Sv2, where v is the mean velocity, F is a coefficient related to 
the viscous drag of the fluid and S is a coefficient related to the losses associated with the 
separation of flow in the stenosis. This behaviour will be seen in the ΔPv-loop as curvilinear 
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segment of the loop where F and S can be determined by fitting the above quadratic to the 
data (12). 
 
In order to fulfil the above conditions, FFR uses potent vasodilators to induce the requisite intra-
coronary condition of stable microvascular resistance. Instantaneous wave-free ratio (iFR) is a 
vasodilator-free pressure-only measure of stenosis severity which takes an alternate approach to 
stabilising microvascular resistance (25). Instead of using the complete cardiac cycle, it is 
calculated during a specific period in diastole – the wave-free period. During this period intra-
coronary flow velocity is significantly higher and microvascular resistance significantly lower than 
that during the remaining phases of the complete cardiac cycle; this is because the large 
fluctuation in resistance occurs during systole, and not in diastole (25).  iFR has been 
demonstrated to have a high classification agreement with established pressure derived (FFR), 
and pressure and flow derived indices (hyperaemic stenosis resistance index) (25, 26) . However, 
the utility of using the wave-free period over any other period in diastole has not been fully 
explored.  In this study we explore how the hemodynamics of the wave-free period differ from that 
of the entire cardiac cycle and of the whole of diastole. We determine the hemodynamic 
characteristics of the wave-free period and their suitability for the pressure-only assessment of 
coronary stenoses.  
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3.3  Method  
3.3.1  Study population 
This study included 56 vessels (42 patients, 82% male) scheduled for coronary angiography 
or PCI at Imperial College London NHS Trust, UK and The Royal Brompton and Harefield 
NHS Trust, UK. In addition to new data, patients were included from part 1 of the ADVISE 
study (6). The patient demographics are consistent with the broad entry criteria used in 
recruitment (Table 1). Exclusion criteria were limited to significant valvular pathology, 
previous coronary artery bypass surgery and weight>200kg. All subjects gave written 
informed consent in accordance with the protocol approved by the local ethics committee 
(NRES 09/H0712/102; NCT01118481). 
 
3.3.2  Study Protocol 
 
3.3.2.1 Cardiac Catheterization 
 Cardiac catheterization was undertaken through the femoral approach. After diagnostic 
angiography, a 0.014inch pressure and Doppler sensor-tipped wire (ComboWire® XT, 
Volcano Corporation, San Diego, CA) was passed into the target vessel via a guiding 
catheter. Pressure equalisation was performed at the tip of the catheter prior to its 
advancement into the distal vessel. 5000iu intravenous heparin was given at the start of the 
procedure. All patients received 300µg intracoronary GTN. 
 
Pressure and flow velocity recordings were made distal to the target vessel coronary 
stenosis at rest.  Mean flow velocity, resistance and trans-stenotic pressure gradient (aortic 
pressure (Pa) - distal intra-coronary pressure (Pd)) was calculated over the complete cardiac 
cycle, the complete diastolic period and over 50 different sampling periods within diastole 
(from the onset of the backward expansion wave (onset of mechanical diastole) to 5ms from 
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the end of diastole) to identify the optimal window for the pressure only assessment of a 
stenosis. Throughout the manuscript we will refer to these different sampling periods, which 
vary at their onset but all have the same end point (5ms from the end of diastole). These 
sampling periods are numbered 1-50, with consecutive sampling periods being 2% shorter 
than the preceding sampling period as shown (Figure 3.01). The instantaneous pressure 
gradient to flow velocity relationship over diastole was also plotted.  FFR was calculated as 
previously described during stable hyperaemia with 140mcg/kg/min adenosine infused via a 
large central vein (13). 
 
3.3.2.2 Hemodynamic Recordings 
The ECG, pressures and flow velocity signals were directly extracted from the digital archive 
of the device console (ComboMap, Volcano Corporation, San Diego, USA). At the end of 
each recording the pressure sensor was withdrawn to the catheter tip to ensure there was no 
pressure drift. Where drift was identified the measurements were repeated. Data were 
analyzed off-line, using a custom software package designed with Matlab (Mathworks, Inc, 
Natick, Mass).  
 
3.3.2.3 Identification of the wave-free period  
Wave intensity analysis was performed according to the methodology described previously 
(Davies et al. Circulation 2006) to identify the wave-free period during each cardiac cycle (7). 
 
The onset and end of the wave-free period was measured for each vessel from both the 
dicrotic notch as described previously and from the onset of mechanical diastole. Mechanical 
diastole (defined by the onset of the backward explansion wave) was selected as the start of 
mechanical diastole. The proportion of the cardiac cycle between the dicrotic notch and the 
end of diastole free of wave activity was termed the wave-free period (as previously 
described) (25). 
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3.3.4 Data Analysis 
 Processing of digital data (pressure, flow velocity, ECG) for the calculation of the various 
indices and intervals discussed (WIA, selection of wave-free diastolic interval, fractional flow 
reserve, hyperaemic stenosis resistance, microvascular resistance and the pressure ratio 
duing the wave-free period) was performed at a workstation using Matlab (Mathworks, Inc, 
Natick, Mass). The indices were calculated using fully automated algorithms.  Statistical 
analysis was performed using STATA (version 11, StataCorp, Texas, USA). The different 
sampling periods during diastole were compared with a paired Students t-test.  Mean values 
calculated over at least 5 cardiac cycles are expressed as mean ± standard deviation of the 
mean unless otherwise stated.  
 
Definition of microvascular resistance: 
Basal microvascular resistance =  
!"!!!  
Trans-stenotic pressure gradient = 𝑃𝑎! − 𝑃𝑑! 𝑃𝑑! = intracoronary pressure distal to stenosis at baseline, 𝑣! = mean flow velocity distal to 
stenosis at baseline. 𝑃𝑎! = aortic pressure at baseline. 
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3.4  Results 
3.4.1 Instantaneous pressure gradient and flow velocity during diastole 
The trans-stenotic pressure gradient changed significantly during diastole.  Peak trans-
stenotic gradient was 11.2±15.2mmHg compared to a minimal value of 2.2±8.6mmHg 
(p<0.001, Figure 3.02 left panel). Flow velocity changed accordingly, peaking at 
30.9±14.0cm/s with a minimal value of 12.5±7.0cm/s (p<0.001, Figure 3.02, right panel). 
Highest flow and lowest microvascular resistance values were obtained at the onset of the 
wave-free period. 
 
Figure 3.03, demonstrates the relationship between the trans-stenotic pressure gradient and 
flow velocity at rest averaged over the entire patient population. There are two phases to this 
relationship (Figure 3b). During the initial phase both the pressure gradient and flow velocity 
increase (black arrow). This corresponds to a period of diastole when there is acceleration of 
blood flow secondary to active relaxation of the myocardium. During this time wave-intensity 
analysis demonstrates that acceleration of blood flow is due to decompression arising from 
the coronary microcirculation. As a result intracoronary pressure during this phase does not 
simply reflect the hemodynamic effect of the stenosis but reflects the composite influence of 
the active effect of myocardial relaxation and the fluid dynamics across the stenosis.  
 
The second phase occurs just after flow velocity has peaked. This coincides with the end of 
the myocardial originating decompression wave, which is coincident with the end of active 
relaxation of the myocardium. For the remainder of diastole blood flow is seen to be passive 
and the trans-stenotic pressure gradient and flow velocity fall together (red arrow). In this 
window of time, there is an almost linear relationship between trans-stenotic pressure 
gradient and flow velocity. During this period, we demonstrate that both wave-intensity 
analysis and the pressure-gradient/flow-velocity loops demonstrate the same findings: that 
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intra-coronary hemodynamics is free of the active accelerative forces of early diastole. 
Therefore, the confounding effect of myocardial activity on intra-coronary pressure is 
minimised and intracoronary hemodynamics are most reflective of the severity of the 
upstream coronary stenosis.  When the wave-containing the early phase of diastole is 
excluded, the relationship between pressure-gradient (ΔP) and flow velocity (v) in the 
remaining (wave-free) period can be seen to fit the recognised curvilinear relationship, 
ΔP=Fv+Sv2, where F is frictional and S is the separation coefficient of the stenosis (12) 
(Figure 3.03).  
 
3.4.2 Duration of the diastolic wave-free period 
The diastolic wave-free period commenced at the end of the backward expansion wave in all 
patients, starting 484.2±61.4 ms after the onset of the cardiac cycle (as defined as the onset 
of the backward compression wave) and ending at the end of diastole. Its mean duration 
was 424.6±123.1ms.  The duration of the wave-free period was strongly determined by the 
length of the RR interval (r2=0.845). Expressing the wave-free period as a fraction of diastole 
(thus accounting for the length of the RR interval), this proportion was more stable, 
occupying 75.8±8.6% of the period between the dicrotic notch and the end of the wave-free 
period. The proportion of diastole taken by the wave-free period was independent of heart 
rate (r2=0.03), mean blood pressure (r2=0.04) and stenosis severity (r2=0.01).  
 
3.4.3 Intra-coronary resistance during the wave-free period  
Across all patients mean micovascular resistance during the wave-free period was 378.4 ± 
161.6 mmHg.s/cm which was significantly lower than during the entire diastolic period, 467.1 
± 194.1mmHg.s/cm (p<0.001), or the mean microvascuar resistance during the whole 
cardiac cycle, 509.7 ± 197 mmHg.s/cm (p<0.001) (Figure 3.04).   
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Analysis of the different sampling periods over diastole (Figure 3.04b) demonstrates 
significant variation during diastole of microvascular resistance. Microvascular resistance 
during the entire diastolic period had significantly more variability than that during the wave-
free period (variance 356.7 (mmHg.s/m)2 diastole vs. 20.7 (mmHg.s/m)2 wave-free period, 
p<0.001). The wave-free period provided the unique combination of low magnitude of 
microvascular resistance with low variance of microvascular resistance (Figure 3.04B). 
 
3.4.4  Identification of the optimal sampling window 
Even within the diastolic wave-free period there was some variation in microvascular 
resistance. For example the last 15% of diastole had significantly higher microvascular 
resistance than the first 15% of the diastolic wave-free period. Indeed, instantaneous 
analysis of microvascular resistance over the cardiac cycle demonstrates that there is an 
increase in microvascular resistance towards the end of diastole as left ventricular end 
diastolic pressure increases (Figure 3.05). When the last 15% of diastole (associated with 
this increase in microvascular resistance) is excluded microvascular resistance during the 
wave-free period can be reduced by a further 7.1±6.6% (378.4±161.6mmHg.s/m vs 
353±148.0mmHg.s/m, p<0.001). Moreover, exclusion of the last 15% of diastole leads to 
significant reduction in the variance of micro-vascular resistance (20.74mmHg.s/m vs 
3.15mmHg.s/m, p<0.001) during the wave-free period (Figure 3.06).  
 
3.4.5 Haemodynamics of the wave-free period vary with stenosis severity 
When the stenoses are divided according to hemodynamic severity by FFR it can be seen 
that the proportional relationship between pressure gradient and flow velocity during the 
diastolic wave-free period remains (Figure 3.07). Furthermore, almost all the data points 
measured fall on the linear aspect of the curvilinear relationship, with a slope that varies in 
proportion to the severity of the lesion, with mild, moderate and severe lesions producing 
significantly different slopes. As a result the pressure difference during the wave-free period 
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of the three categories of mild, moderate and severe lesions is significantly different during 
baseline conditions (mean pressure difference: 4.4±4.2mmHg mild vs 13.3±12.2mmHg 
moderate and 55.7±11.1 mmHg severe stenoses, p<0.001).  
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3.5  Discussion 
This study has found that during the diastolic wave-free period, microvascular resistance has 
significantly lower variability and reduced magnitude than either the complete cardiac cycle 
or over the entire diastolic period. Second, the duration of the wave-free period as a 
proportion of diastole is consistent across patients with varying hemodynamics and stenosis 
severity. Third, during this wave-free period the trans-stenotic pressure difference is 
proportional to underlying flow velocity. 
 
3.5.1  Myocardial contraction and relaxation confounds the assessment of coronary 
stenoses 
Coronary blood flow is unique. Unlike other systemic arteries, blood flow in a coronary artery 
is caused by changes in pressure at both the proximal and distal ends of the vessel (7, 10). 
This means that the pressure distal to a coronary artery stenosis does not simply reflect the 
severity of the stenosis but is a composite of residual proximal pressure and pressure arising 
from the contraction and relaxation of the myocardium surrounding the distal blood vessels 
(7,10). Trans-stenotic pressure gradients at certain times in the cardiac cycle can therefore 
reflect the hemodynamic significance of the stenosis itself less well (12).  During systole 
myocardial distal contribution to intra-coronary pressure is known to be important, but our 
findings suggest that distal contributions also remain significant in early diastole. In early 
diastole, wave-intensity analysis demonstrates that intra-coronary blood flow is accelerated 
by a distal-originating decompression wave arising from relaxation of the myocardium (7). 
The confounding effect of this wave on the accurate assessment of a coronary stenosis is 
evident on the loop of pressure gradient against flow velocity.  Perhaps because of the 
inherent inertia of blood, during the backward-expansion wave the trans-stenotic pressure 
gradient rises more quickly than flow. During these periods, the overly simplistic Ohms law 
relating pressure gradient and flow over-estimates the resistance of the stenosis. Therefore, 
in order to isolate the hemodynamics of the stenosis from distal myocardial pressure, 
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assessment should ideally therefore occur in the absence of any accelerative or decelerative 
forces (12).    
These findings are consistent with the findings of Gould in the canine model over 30 years 
ago in which the pressure gradient flow relationship of coronary stenoses were studied at 
rest (12). Using pressure-gradient/flow-velocity loops Gould demonstrated the importance of 
assessing coronary stenosis severity in a period of the cardiac cycle ‘free of accelerative and 
decelerative forces’. We have previously used wave-intensity analysis to also identify a 
period of passive blood flow within the cardiac cycle, free of accelerative and decelerative 
forces (7, 25, 26). In our data, applying the traditional pressure-gradient /flow-velocity loops, 
shows that the period identified by wave- intensity analysis is somewhat similar to the period 
of passive blood flow identified by Gould (12). Regardless of this similarity, the 
proportionality of trans-stenotic pressure and flow velocity during the wave-free period 
confirms the physiological basis of determining stenosis severity during the wave-free 
period.  
These findings have several implications for pressure-only assessment of coronary stenoses 
and specifically the instantaneous wave-free ratio. First, the relative independence of intra-
coronary pressure from the confounding effect of myocardial activity during the wave-free 
period confirms the diastolic wave-free period as the most suitable window within the cardiac 
cycle and more specifically within diastole for a pressure-only assessment of the 
physiological significance of a stenosis. This is because by excluding the period of the 
cardiac cycle when intra-coronary pressure is influenced by contraction and relaxation of the 
myocardium, intra-coronary pressure most accurately reflects the effect of the upstream 
stenosis on coronary blood flow – the Gould principle (12). Second, the proportional 
relationship of pressure gradient and flow velocity during the wave-free period permits 
pressure alone to be used to make inferences about underlying flow-velocity and this varies 
according to stenosis severity. This proportional relationship is not present throughout the 
complete diastolic period. On this physiological basis, pressure alone cannot be used as a 
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surrogate for flow during the whole diastolic period under baseline conditions. Third, the 
stability of the wave-free period demonstrates why isolation of this period can be reliably 
performed using the pressure waveform alone. Pioneers in this field that have previously 
isolated this period have required manual post-hoc analysis of the pressure and flow data for 
its accurate isolation (12, 27, 28). This can be challenging outside expert hands and has 
therefore limited the clinical adoption of indices using this period (28). Automated isolation of 
the wave-free period, using pressure alone, circumvents many of these limitations because it 
can be done without manual selection in real time during cardiac catheterisation.  
3.5.2  Optimising the signal-to-noise ratio when assessing coronary stenoses 
Evaluating biological signals involves preferentially emphasising signal and de-emphasising 
noise. For pressure-only physiological assessment of coronary stenosis, the signal is the 
drop in pressure across the lesion caused by flow across it. The noise is the disturbances in 
pressure arising distally because the myocardium compresses and decompresses the 
microcirculation.  
If measurements are to be made throughout the cardiac cycle, then noise will always be 
included, but the signal can be increased by pharmacologically increasing flow, as has been 
well documented with FFR. 
If precise automated selection is available, however, a segment of the cardiac cycle can be 
secured in which noise is naturally minimised and simultaneously signal naturally enhanced. 
Indeed we demonstrate that completely automated real-time phasic analysis of the cardiac 
cycle can isolate the most informative data regarding the stenosis (during the diastolic wave-
free period when intra-coronary flow is intrinsically at its highest) and set aside the least 
informative (systole and early diastole) (12, 25, 26). As a result the period of the cardiac 
cycle most relevant to the hemodynamics of the coronary stenosis can be isolated – easily, 
in real time and without the need to administer pharmacological agents to increase flow. This 
elimination of waves and natural increase in flow velocity is the physiological basis of iFR in 
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signal-to-noise terms. The computational effort of automatically calculating this time window, 
in effect, replaces the clinical effort of applying adenosine. However, by obviating the need 
for vasodilators this approach circumvents a key limitation of pharmacological approaches to 
signal optimisation – a variable response to the drug between patients. Indeed, by drawing 
on intrinsic physiology, the wave-free period provides a more consistent reduction in 
microvascular resistance and increase in flow velocity than that possible during adenosine 
mediated FFR (26).  
 
3.5.3 Clinical Implications 
The instantaneous wave-free ratio can classify patients similarly to FFR, as seen in the 
ADVISE study and ADVISE registry (25, 29). However, there has been some speculation 
regarding the physiological basis of the index and the significance of isolating the wave-free 
period (30, 31, 32). The detailed analysis of diastole in this study differentiates the wave free 
period from the rest of diastole and from systole. It delineates why the wave-free period is 
physiologically the most suitable period within diastole for the assessment of a coronary 
stenosis. Indeed, incorrect selection of the time, can provide unsatisfactory results as has 
been highlighted (30, 32) and subsequently corrected (33).   
 
While newer indices of the severity of coronary stenosis based on basal measurements such as 
iFR offer many advantages over indices based on drug-induced hyperaemic conditions such as 
FFR, they have not been tested as extensively clinically. Until the clinical tests are completed, it 
could be argued that similar methods could be applied to hyperaemia-based measurement, i.e. 
identifying periods during the cardiac cycle when the microvascular resistance is naturally 
minimised, could result in improved measurements of FFR that are less sensitive to variations in 
the patient response to vasodilatory drugs.  
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3.6  Study limitations 
The number of patients is not large compared to studies that have only addressed pressure or 
have not addressed timing within the cardiac cycle. The proportion of diastole of the wave-free 
period may vary slightly. However, this study recruited a wide range of cardiac patients and the 
low standard deviation of the diastolic proportion suggests that the diastolic window identified 
should be applicable to the general patient population.  Additionally, this is the largest study to 
date exploring pressure gradient – flow velocity curves and their relation to wave-intensity in 
humans. 
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Conclusion 
The diastolic wave-free period is a distinct period in diastole that uniquely provides the requisite intra-
coronary conditions for the pressure only assessment of a coronary stenosis. Its automated detection 
isolates the fluid dynamics of the stenosis in real time providing a physiological alternative to the 
traditional pharmacological approach to lesion assessment. 
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Table 3.1: 
 
   
Stenoses, %(n)
Male 83.9(47)
Age 66.2±9.2
Risk Factors
Smoker 32.1(18)
Diabetic 26.8(15)
Hypertension 39.3(22)
Family History 25(14)
Territory
LAD 55.4(31)
Cx 25(14)
RCA 19.6(11)
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Figure 3.03: Instantaneous trans-stenotic pressure gradient - flow
 velocity 
relationship 
 There are tw
o phases of the trans-stenotic pressure gradient flow
 velocity relationship during 
diastole. In the first phase (black arrow
) trans-stenotic pressure rises faster than flow
 velocity, 
as a result it over estim
ates the underlying flow
 conditions in the coronary (A
&
B
). The second 
phase starts as the trans-stenotic gradient and flow
 velocity peak and at the onset of the 
w
ave-free period (B
). From
 this point onw
ards both trans-stenotic pressure gradient and flow
 
velocity decline in a linear fashion w
hich is consistent w
ith stable m
icrovascular resistance.  
W
hen the first phase of diastole is excluded (due to the confounding effect of the accelerative 
forces secondary to the m
icrocirculatory decom
pression w
ave) it can be seen that the phase 
of diastole free of accelerative forces is synonym
ous w
ith the w
ave-free period (C
). 
Furtherm
ore the pressure gradient and flow
 velocity relationship during this period fits the 
traditional quadratic equation Δ
P
=Fv+S
v
2 (w
here F is frictional and S
 is the separation 
coefficient of the stenosis) (data averaged from
 56 patients). 
 73 
 
F
ig
u
re 3.04: D
ifferen
tiatin
g
 th
e w
ave-free p
erio
d
 fro
m
 th
e rest o
f d
iasto
le 
 A
. M
icrovascular resistance is significantly low
er during the diastole w
ave-free period w
hen 
com
pared w
ith the rest of diastole 
B
. A
 plot dem
onstrating the m
agnitude of m
icrovascular resistance and intra-beat variance of 
m
icrovascular resistance for each sam
ple period. T
he optim
al sam
ple period for the 
calculation of a pressure derived index com
bines the low
est m
agnitude of resistance w
ith the 
low
est intra-beat variability of resistance. T
his occurred in the sam
ple period including the 
w
hole of the last 75%
 of diastole – the w
ave-free period. It can be seen that m
icrovascular 
resistance during the w
hole of diastole w
as not only greater in m
agnitude but also had greater 
intra-beat variability(data averaged from
 56 patients).  
 74 
 
F
ig
u
re 3.05: In
stan
tan
eo
u
s m
icro
vascu
lar resistan
ce d
u
rin
g
 d
iasto
le an
d
 th
e w
ave-
free p
erio
d
. 
 It can be seen that m
icrovascular resistance varies considerably during diastole. It initially falls 
and then plateaus during the m
ajority of the w
ave-free period. H
ow
ever, there is a sharp increase 
in m
icrovascular resistance at the end of diastole, encom
passing the last 15%
 of diastole. 
E
xclusion of this period m
ay m
ake the hem
odynam
ics of the w
ave-free period m
ore favourable for 
a pressure derived stenosis assessm
ent (data averaged from
 56 patients).  
 
 
75 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 3.06: Exclusion of the last 15%
 of 
diastole provides lower m
icrovascular 
resistance and lower variation of 
resistance 
 Upper panel, a plot of m
icrovascular resistance for 
each sam
ple period using the original end point for 
the sam
ple periods, 5m
s from
 the end of diastole 
(red dots) com
pared to that using an end point 
that is 15%
 from
 the end of diastole (gold dots). It 
can be seen that the latter provides lower 
m
icrovascular resistance through exclusion of the 
increase in m
icrovascular resistance that occurs at 
the end of diastole as the m
yocardium
 prepares 
for the next cardiac cycle. Lower panel, a plot of 
the variance of m
icrovascular resistance within 
each sam
ple period, using the original (m
inus 5m
s 
end point) and new (m
inus 15%
) end point; it can 
be seen that the ‘m
inus 15%’ end point 
significantly reduces the variation of resistance 
within each sam
ple period (data averaged from
 56 
patients).  
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4.0 Development and validation of a new adenosine-independent 
index of stenosis severity from coronary wave intensity analysis  
Results of the ADVISE (Adenosine Vasodilator Independent Stenosis 
Evaluation) study 
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4.1  Abstract 
4.1.2  Background 
Assessment of stenosis severity with fractional flow reserve (FFR) requires that coronary 
microvascular resistance is stable and minimised.  This is usually achieved by administration of 
pharmacological agents such as adenosine.  In this 2 part study we determine if there is a time 
when microvascular resistance is naturally minimised at rest and (2) assess the diagnostic 
efficiency, compared to FFR, of a new pressure–derived adenosine-free index of stenosis 
severity over that time. 
4.1.3  Method 
157 stenoses were assessed. In part 1; 39 stenoses, intracoronary pressure and flow-velocity 
were measured distal to the stenosis; in part 2, 118 stenoses, intracoronary pressure alone was 
measured. Measurements were made at baseline and under pharmacological vasodilatation with 
adenosine.  
4.1.4  Results 
Wave intensity analysis identified a wave-free period where microvascular resistance at rest is 
similar in variability and magnitude (CV:0.08±0.06 and 284±147mmHg.s/m) to those during FFR 
(CV:0.08±0.06 and 302±315mmHg.s/m, p=NS for both). The resting distal to proximal pressure 
ratio during this period, the instantaneous wave-Free Ratio (iFR), correlated closely with FFR 
(r=0.9, p<0.001) with excellent diagnostic efficiency (receiver operating characteristic area under 
curve of 93%, at FFR<0.8), specificity, sensitivity, negative and positive predictive values of 91%, 
85%, 85% and 91%, respectively.  
4.1.5 Conclusion 
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microvascular resistance is naturally constant and minimised during the wave-free period.  The 
instantaneous wave-Free Ratio (iFR) calculated over this period produces a drug-free index of 
stenosis severity comparable to FFR. 
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4.2  Introduction 
Intracoronary physiological indices enable cardiologists to circumvent the limitations of 
angiography when assessing the hemodynamic impact of stenoses(16, 17). Functional 
assessment of stenoses in the catheterisation laboratory can be performed by measuring 
intracoronary flow velocity (coronary flow velocity reserve), pressure (fractional flow reserve, 
FFR), or both (hyperaemic stenotic resistance)(5, 21). FFR is the most widely used index in 
clinical practice, being supported by a large body of evidence demonstrating its value in 
clinical decision-making. When used to guide percutaneous interventions, FFR has been 
shown to improve clinical outcomes and procedural cost-efficiency (14-17). 
 
The cornerstone of FFR is the linear relationship between pressure and flow under 
conditions of constant (and minimised) microcirculatory resistance (5). Under such 
conditions pressure and flow are assumed to be directly proportional, and a fall in pressure 
across a stenosis reflects a reduction in blood flow to the dependent myocardium.  However 
even after administration of potent pharmacological agents such as adenosine, 
microvascular resistance is not static, but instead, fluctuates in a phasic pattern (akin to 
impedance in an alternating current electrical circuit) throughout the cardiac cycle (Figure 
4.01).   These fluctuations reflect the interaction between the myocardium and 
microvasculature during systole (high microvascular resistance, compression of 
microvasculature) and diastole (lower microvascular resistance, decompression of the 
microvasculature)(8).  Accordingly to minimise these effects, FFR is calculated during 
hyperaemia (maximal flow to the vascular bed) and time-averaged over several cardiac 
cycles to ensure constant and minimal microvascular resistance.  
 
Whilst time-averaging and the administration of pharmacological vasodilators was a 
pragmatic solution to achieving appropriate conditions to calculate FFR when computational 
power was limited, it may now be unnecessary if a time period could be identified from the 
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resting pressure waveform when microvascular resistance is naturally constant and 
minimised. Theoretically during such a period in the cardiac cycle intra-coronary pressure 
and flow would be proportional.  Consequently a ratio of trans-stenotic pressures would 
provide a measure of the severity of a coronary stenosis.   Identification of such a period 
would negate the need for administration of pharmacological agents such as adenosine, 
saving time, reducing costs and side-effects, and leading to improved adoption in the cardiac 
catheter laboratory.      
 
In the first part of this study, we identified the existence of a diastolic interval in which 
microvascular resistance at rest is equivalent to time-averaged microvascular resistance 
during FFR measurements. We hypothesise that pressure measurements obtained 
selectively at this specific interval of the cardiac cycle would allow a new pressure derived 
index of stenosis severity that does not require pharmacological vasodilatation, we term this 
the instantaneous wave-free ratio (iFR). In the second part of the study, this hypothesis was 
tested in a larger population by comparing iFR and FFR measurements. 
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4.3  Methods 
4.3.1  Patients 
This multi-centre international, non-randomised study recruited 131 patients (63±10 year, 
85% male) scheduled for coronary angiography or PCI at three sites (Imperial College 
Healthcare NHS trust, London, UK, Cardiovascular Institute, Hospital Clínico San Carlos, 
Madrid, Spain, and Royal Brompton & Harefield NHS trust, London, UK). The patient 
demographics are consistent with the broad entry criteria used in recruitment (Table 4.1). 
Exclusion criteria were limited to significant valvular pathology, previous coronary artery 
bypass surgery, contra-indication to adenosine administration (e.g. asthma, chronic 
obstructive pulmonary disease (COPD), heart rate<50 beats per minute and systolic blood 
pressure <90mmHg), elevated troponin and weight>200kg. All subjects gave written 
informed consent in accordance with the protocol approved by the local ethics committee 
(NRES ref: 09/H0712/102; NCT01118481). 
 
4.3.2 Study Protocol 
4.3.2.1 Cardiac Catheterization  
In this 2 part study the patients were divided into two groups providing a total of 157 
stenoses (Group 1 39 stenoses and Group 2 118 stenoses) (Figure 4.02).  
 
Part 1 (39 stenoses): Cardiac catheterization was undertaken through the femoral approach. 
After diagnostic angiography, a 0.014inch pressure and Doppler sensor-tipped wire 
(ComboWire® XT, Volcano Corporation, San Diego, CA) was passed into the target vessel 
via a guiding catheter. Pressure equalisation was performed at the tip of the catheter prior to 
its advancement distal to the stenosis. Pressure and flow velocity recordings were then 
made at baseline. Adenosine was then infused (140 micrograms/kg/min) via a femoral 
venous sheath and pressure and flow velocity measurements repeated under conditions of 
maximal pharmacological vasodilatation.  
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Part  2 (118 stenoses): Cardiac catheterisation was undertaken via either femoral or radial 
approach. Adenosine doses of 140 micrograms/mg/min (via femoral vein) or up to 120 
micrograms (intracoronary) were used to induce vasodilatation. After diagnostic 
angiography, a 0.014inch pressure sensor-tipped wire (PrimeWire, Volcano Corp, or Radi 
PressureWire, St Jude Medical, Minnesota, USA) was equalised and then advanced distal.  
Pressure measurements were made at baseline and under maximal pharmacological 
vasodilatation.  
 
In both groups 5000iu intravenous heparin was given at the start of the procedure and 300 
micrograms of intracoronary nitrates were routinely given prior to haemodynamic 
measurements. 
 
4.3.2.2 Haemodynamic Recordings 
When the ComboWire or PrimeWire pressure wire was used, the ECG, pressures and flow 
velocity signals were directly extracted from the digital archive of the device console 
(ComboMap®). When the Radi PressureWire system was used, continuous digital 
acquisition and storage of the ECG, aortic, and intracoronary pressures were performed 
using a 12-bit resolution analog-to-digital converter (DI-200 PGL, DataQ Instruments, Akron, 
Ohio) controlled by dedicated software (WinDaq 200, DataQ Instruments) in a personal 
computer. The sampling rate was 114 Hz per channel.  
 
At the end of each recording the pressure sensor was returned to the catheter tip to ensure 
there was no pressure drift. Where drift was identified the measurements were repeated. 
Data were analyzed off-line, using a custom software package designed with Matlab 
(Mathworks, Inc, Natick, Mass). 
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4.3.2.3 Identification of period of constant and minimal microvascular resistance 
Changes in coronary haemodynamics over the cardiac cycle were assessed by calculating 
instantaneous resistance and by applying wave intensity analysis. An index of resistance 
was calculated as the ratio between pressure and flow velocity. Wave intensity analysis was 
performed according to the methodology described previously (7) to identify wave-free 
periods (Figure 4.01, upper panel).  During this wave-free period the onset of minimal 
microvascular resistance was identified, and its value calculated for each patient. It was not 
possible to calculate microvascular resistance in 2 cases due to poor tracking of the velocity 
envelope during diastole. Mean microvascular resistance and its coefficient of variation were 
then calculated over a minimum of three beats.  
 
In order to minimize any selection bias and truly assess the diagnostic efficiency of our 
index, we designed this study to include all the cardiac patients that FFR is used in routinely 
in clinical practice (including single vessel, multi vessel, and diabetic patients). We used both 
intra-coronary and intra-venous adenosine and pressure wires from RADI and Volcano.  
FFR was measured in the standard way (5, 15-17), and used to guide the clinical case.  
However, the invasive measurement team was blind to the iFR value, which was calculated 
offline using a fully automated Matlab algorithm (Mathworks, Inc, Natick, Mass).  
 
4.3.4  Calculation of the instantaneous wave-free ratio (iFR) 
Wave intensity analysis was used to identify the backward-travelling waves (Equation 3.1). 
The onset of diastole was identified from the dicrotic notch, and the diastolic wave-free 
window was calculated from wave-intenisty analysis (7). 
 
Instantaneous wave-free ratio (iFR) was calculated as the mean pressure distal to the 
stenosis during the diastolic wave-free period  (𝑃𝑑!"#$!!"##  !"#$%&) divided by the mean aortic 
pressure (𝑃𝑎!"#$!!"##  !"#$%&) during the diastolic wave-free period (Equation 3.2). All 
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analyses were performed in a fully automated manner negating the need for manual 
selection of data time points.  
 
Equation 3.1 
Backward-travelling waves = 𝑊𝐼! = − !!!" !"!" −   𝜌𝑐 !"!" !      
Start of wave-free period = time (𝑊𝐼!(diastole) > 0) 
End of wave-free period = end of diastole-5ms 
Wave-free period = start of wave-free period to end of wave-free period  
 
Equation 3.2 
instantaneous wave-free ratio(iFR)  =   𝑷𝒅𝒘𝒂𝒗𝒆!𝒇𝒓𝒆𝒆  𝒑𝒆𝒓𝒊𝒐𝒅𝑷𝒂𝒘𝒂𝒗𝒆!𝒇𝒓𝒆𝒆  𝒑𝒆𝒓𝒊𝒐𝒅        
 
Where, 𝜌  is the density of blood (taken as 1050kgm-3), 𝑐 is the wave speed calculated using 
the single-point equation (7,11), 𝑑𝑃 is the incremental change in coronary artery pressure, 
and 𝑑𝑈 the incremental change in blood viscosity. 
 
4.3.5 Data Analysis 
Processing of digital data (pressure, flow velocity, EKG) for the calculation of the various 
indices and intervals discussed (WIA, microvascular resistance, FFR, selection of wave-free 
diastolic interval, iFR) was performed at a workstation using Matlab (Mathworks, Inc, Natick, 
Mass), Statistical analysis was performed using STATA (version 11)(StataCorp, Texas, 
USA). A paired Student’s t-test was used to compare within patients. The proportional 
change in microvascular resistance during the cardiac cycle was referenced to baseline 
mean microvascular resistance. The relationship between FFR and iFR for the entire patient 
population and all subsequent sub-group analyses was quantified with a Pearson’s product 
moment correlation coefficient.  Receiver operator characteristics curves (ROC) were used 
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to estimate diagnostic efficiency of iFR and to identify the most appropriate cut off value 
when compared to the FFR treatment threshold of 0.8. Mean values are expressed as 
mean±standard deviation of the mean.  A repeated measures analysis was performed by 
comparing the iFR from the first half of the recording with the value from the second half of 
the recording using a paired Students t-test. The relationship of heart rate and blood 
pressure to iFR was quantified with a Pearson’s product moment correlation coefficient. A p-
value of <0.05 was deemed significant. 
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4.4  Results 
4.4.1 Identification of period of stable microvascular resistance in the cardiac cycle 
 
In each of the 39 stenoses included in group 1 intracoronary pressure, flow velocity and 
microvascular resistance was analysed prior to and during the administration of adenosine. 
Wave intensity analysis allowed identification of a wave-free period after the backward 
decompression wave when wave intensity and microcirculatory originating pressure return to 
zero (Figure 4.01, panel 1&2). The mean duration of this period was 354±78ms (75±6% of 
diastole), starting 112±26ms after the onset of diastole. Intra-coronary microvascular 
resistance remained minimised and stable throughout this wave-free period (Figure 4.01, 
panel 3). 
 
4.4.2 Microvascular resistance throughout the cardiac cycle at rest and with 
pharmacological vasodilatation 
Adenosine administration caused the mean intracoronary microvascular resistance over the 
entire cardiac cycle to fall by 51% (613±310 mmHg s/m vs 302±315 mmHg s/m, p<0.001). 
This was predominantly due to a 75% reduction in the systolic contribution to microvascular 
resistance (Δ systolic resistance 461mmHg s/m, p<0.001, Figure 4.03).  
 
Both magnitude and variability of intracoronary microvascular resistance identified during the 
wave-free period was similar to that achieved over the entire cardiac cycle during 
pharmacological vasodilatation. The magnitude of microvascular resistance during the wave-
free period was 284±147 mmHg s/m compared with 302±315 mmHg s/m during 
pharmacological vasodilatation (p=0.70, Figure 4.04, left panel (A)). The coefficient of 
variation of microvascular resistance during the wave-free period was 0.08±0.06 compared 
with 0.08±0.06 during pharmacological vasodilatation (p=0.96, Figure 4.04, right panel (B)). 
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4.4.3 Reproducibility and Diagnostic characteristics of iFR 
iFR was calculated for each stenosis using the wave-free time window as defined above and 
this was compared with FFR.  iFR was found to be closely correlated to FFR(r=0.90, 
y=1.0x+0.03, Figure 4.05). Using the established FFR cut-off threshold of 0.8 to define a 
positive result, a receiver operator characteristic curve was used to identify the optimal iFR 
cut-off (0.83) with the greatest diagnostic efficiency. The receiver operating characteristic 
area under curve was 93% (Figure 4.06, left panel). The false negative and false positive 
data for iFR is demonstrated in Figure 4.07 (right panel). This demonstrates that the positive 
predictive value of iFR was 91%; the negative predictive value was 85% with sensitivity, 
specificity of 85%, and 91% respectively.  
 
This relationship persisted throughout our sub-group analysis, with similar levels of 
correlation independent of type of pressure wire, route of pharmacological vasodilator 
administration, single or multi vessel disease (Table 3.2), or heart rate ([range 46-120/min] 
r2=0.016), systolic (r2=0.001) and diastolic pressure (r2=0.005). Furthermore the close 
correlation of iFR to FFR remained with left coronary (r=0.90) and right coronary arteries 
(r=0.89) with a diagnostic accuracy in the right coronary of 91%, consistent with the entire 
cohort (Figure 4.07). 
 
The Bland Altman analysis also demonstrates good agreement between measures with a 
mean difference between FFR and iFR of -0.05±0.19. A repeated measures analysis of iFR 
was made in 149 stenoses, which demonstrated a close relationship between the two 
successive measurements (r=0.996, p<0.001, Figure 4.07) with a mean difference between 
iFR measurements of -0.0005±0.002 (p=0.78).  
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4. 5 Discussion 
The main conclusions of this study are: 1) when selectively measured within a defined 
diastolic wave-free period, resting coronary microvascular resistance values are similar to 
those observed during adenosine mediated FFR; 2) the ratio of distal to proximal pressures 
during this wave-free period produces an index (instantaneous wave-free ratio, iFR) that 
correlates closely with FFR.  
 
4.5.1 The importance of constant intracoronary microvascular resistance in the 
functional assessment of stenoses 
Coronary blood flow is unique in that it is determined not only by variations in pressure 
arising proximally (as in the aorta and other systemic arteries) but also concurrent variations 
arising distally in the microcirculation (Figure 4.08) (7).   It is considered inaccurate to assess 
the severity of a coronary stenosis by simply measuring the fall in mean or peak pressure 
across a stenosis, under basal conditions over the entire cardiac cycle, because distal 
coronary pressure is not simply a residuum of the pressure transmitted from the aortic end of 
the vessel (Figure 4.08. upper panel), but is also due to a pressure component arising from 
active compression and decompression of the coronary microcirculation (Figure 4.08, lower 
panel).  These distal influences cause dramatic variations in the instantaneous ratio between 
pressure and flow (a simple index of intracoronary microvascular resistance). Wave intensity 
analysis can be used to distinguish distal microcirculatory-originating influences from 
proximally-originating influences transmitted from the aorta (7). The most extreme examples 
of such variations are the rapid rise of pressure in early systole and the rapid fall in early 
diastole. In early systole, pressure rises rapidly but flow does not, and so the index of 
intracoronary microvascular resistance rises rapidly. The rapid rise in pressure without 
corresponding rise in flow is caused by near perfect matching of compression waves arising 
from the aorta and coronary microcirculation during most of systole (7) (Figure 4.01, top 
panel). In early diastole, the converse happens; pressure falls while flow accelerates, and so 
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the index of intracoronary microvascular resistance falls rapidly. This occurs because the 
microvasculature is suddenly decompressed, causing blood to be sucked in to the coronary 
microcirculation (Figure 4.01). After this brief, but rapid, phase of pressure decline, pressure 
and flow then passively decline together slowly.  During this gradual decline phase, which 
extends for the majority of diastole, the index of coronary microvascular resistance is close 
to minimal and is stable because there is no further wave activity arising from either end of 
the coronary artery. 
 
Pressure-derived flow indices of coronary stenosis severity such as FFR depend on the 
proportional relationship of pressure to flow which occurs when microvascular resistance is 
stable (5); this is only the case for part of the cardiac cycle. Pioneering scientists seeking 
clinically-applicable methods developed highly refined approaches to circumvent the 
computational limitations of the day by administering pharmacological agents such as 
adenosine (5).  As we demonstrate these potent vasodilator agents reduce the dramatic 
variation in microvascular resistance predominantly by reducing the systolic portion of 
resistance (Figure 4.03 & 4.05), to obtain a stable and minimised microvascular resistance 
value.  
 
Recent advances in real-time processing now permit automatic selection of the diastolic 
wave-free period, using measurements of pressure alone, that provides this stable and 
minimal resistance value without having to administer vasodilator agents. During this 
diastolic wave-free period, coronary flow is predominantly determined by the passive 
pressure gradient between the proximal and distal ends of the vessel, analogous to water 
flowing down a pipe.  This natural state of stable and minimised microvascular resistance 
occurs spontaneously in every cardiac cycle, creating an opportunity to calculate a pressure-
derived index without the need for pharmacological intervention.   
 
4.5.2 Identification of the wave-free diastolic window 
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We identified in all patients a period in diastole when microvascular resistance is stable. 
Across all individual patients the start of this window was 112±26 ms after the onset of 
diastole (25±6% into diastole) and the end was the end of diastole. For automatic 
computation, we consider it practical to use an algorithmic definition of the time window that 
begins 25% of the way into diastole (after the early unwanted variations) and ends 5 ms 
before the end of diastole, allowing 75% of diastole during which pressure measurements 
can be made. 
 
4.5.3 iFR as a tool for instant diagnosis – the challenge of minor uncertainty of FFR 
Using an all-comers selection criteria similar to the FAME study (16), iFR was found to agree 
closely with FFR with a diagnostic efficiency (AUC) of 93%. This was seen consistently 
across all subgroups analysed (multi-vessel, single vessel, right and left coronary arteries) 
and independent of the method of assessment (intracoronary vs intravenous adenosine or 
RADI vs Volcano pressure wire) (Table 1).  
 
The variability in FFR is small (34) however, as with any biological measure, it is known to 
vary slightly from one measurement to the next and therefore no technique can correlate 
perfectly with it. We demonstrate that the variability in iFR is also small. We speculate that 
his occurs for 2 main reasons.  First, spontaneous beat-to-beat fluctuations are most 
exaggerated during systole (included in FFR, but excluded by definition in iFR).  Second, 
when ectopic or other unwanted disturbances occur, FFR relies on averaging multiple beats 
to ‘dilute’ their effects, while iFR matches proximal and distal pressures beat-by-beat basis 
by performing a paired comparison between each “mother” aortic diastolic pressure 
component and its own corresponding “daughter” distal diastolic pressure component, 
resulting in more stable values even during arrhythmia (Figure 4.10).   Categorisation using 
iFR was found to agree with categorisation using FFR in 88% of cases treating FFR as a 
perfect gold standard.  
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4.5.4 Clinical Implications of iFR 
Fractional flow reserve has been revolutionary in implementing intracoronary physiology in 
clinical practice. Its success is a reflection of the simplicity of the technique and to 
accumulation of clinical evidence demonstrating the safety of adopting a FFR guided 
approach to revascularisation (14-17). FFR is currently recommended as a surrogate of 
ischemia detection tests in the catheterisation laboratory in clinical practice guidelines(31) 
and, compared with angiography guidance, improves patient outcomes, including mortality, 
whilst decreasing procedural time and costs when used in PCI (15,16). 
 
In spite of this, the use of FFR is far from universal, being performed in only 6% of PCI 
procedures in the USA (36). The need to give adenosine has been highlighted as one of the 
reasons for this poor adoption rate (36). There are several reasons that may explain the 
reluctance of physicians to use adenosine. First, in addition to costs, the clinical effort of 
administering adenosine is not trivial, and so it has to be actively chosen on each occasion. 
Second, some patients have contraindications such as asthma, severe COPD, hypotension 
or bradycardia.  Third, most patients find it uncomfortable.  Fourth, it may require central 
venous access which might otherwise not be necessary for the procedure (37).  Finally, 
initial adenosine response may be incomplete in some patients and this may be difficult to 
predict reliably in advance (38-40). Thus, a wider use of intracoronary physiology would be 
expected if the technique is simplified even further. iFR would circumnavigate these issues 
permitting the benefits of FFR to be accessible to a wider population, at lower cost, less 
patient discomfort and shorter procedural times.    
 
This study’s cohort of patients reflects a wide demographic spectrum and is similar to that of 
the FAME study (16). The results of this study could be followed by further validation of iFR, 
in a larger cohort to better establish the diagnostic efficiency of each technique in the same 
study population. Although this appears as a pre-requisite before iFR can be proposed as an 
alternative to FFR in all contexts the excellent reproducibility and agreement in classification 
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with FFR (within the biological variability of fractional flow reserve) suggest that iFR will 
expand intracoronary functional assessment to circumstances where administration of 
adenosine is not desirable.  
 
A final word should be dedicated to previous research on the use of diastolic pressures for 
FFR calculation, so-called diastolic FFR (41,42). The validation of diastolic FFR 
demonstrated that diastolic-only pressure measurements can be used to estimate stenosis 
severity with the same diagnostic efficiency as FFR, which uses cycle-averaged pressure 
measurements (41). This supports the concept that systolic flow can be neglected in the 
pressure-derived indices like diastolic FFR and iFR. The optimal cut-off value to identify 
ischemia generating stenoses in that study was slightly higher for diastolic FFR (0.76) than 
for FFR (0.75) (41), a fact that is in agreement with the differences found in our study 
between iFR (0.83) and the currently recommended 0.80 FFR cut-off value. However, major 
differences between diastolic FFR and iFR should be noted: 1) like FFR, diastolic FFR 
requires the use of adenosine and 2) measurements were obtained throughout diastole, and 
not selectively at a specific wave-free interval. As discussed above, the use of this wave-free 
period by iFR, when coronary microvascular resistance remains unchanged and minimal, 
provides a measure that closely correlates with FFR. 
 
4.6  Study limitations 
There is no gold standard ischaemia test. We chose FFR because it is quantitative and 
specific to a vessel, has been validated against three non invasive tests, has robust long 
term clinical outcome data and is the investigation recommended by cardiology guidelines 
for assessment of intermediate stenoses in the cardiac catheter laboratory.  However there 
remains a possibility that any disagreement between the two indices may reflect the 
diagnostic accuracy of FFR rather than iFR.  
 
 
 
94 
This pilot study suggests an iFR value of 0.83 provides optimal agreement with an FFR of 
0.8.  Several hypothesis can be put forward to explain this difference in optimal cut-off 
values. First, since the optimal cut-off value for diastolic FFR, a diastolic-only pressure 
derived method like iFR, is also slightly higher that for FFR (41), it is possible that this 
difference may be genuine due to differences in how the indices are calculated. Second, it 
may result from subtle differences between pharmacological stabilisation of microvascular 
resistance compared to that which occurs naturally in the wave-free period. Finally, the 
possibility that it may be artefactual, given the relatively small size of our study, cannot be 
ruled out. With a larger patient population any differences might be further explored, and this 
cut off may alter in a similar manner to FFR during its development.  Therefore, future 
studies are needed to address the diagnostic accuracy between FFR and iFR and the best 
cut-off value for iFR. 
 
Intracoronary and intravenous administration of adenosine can have differing effects on 
peripheral and coronary arterial circulations.  To mitigate against potential confounding from 
one or other of these administration routes we decided to include both intravenous and 
intracoronary administration in our study.   In sub-analyses of our results, we have found no 
significant differences between either routes of administration (Table 2). Finally, a similar 
agreement between iFR and FFR values was documented in the right and left coronary 
artery, in spite of the more predominant systolic component of flow in the right coronary 
artery. 
4.7  Conclusions 
The existence of a wave-free period in diastole when coronary microvascular resistance is 
constant and minimal opens the possibility of performing pressure derived stenosis 
assessment without the need for pharmacological vasodilatation. Instantaneous wave-free 
ratio (iFR), a new index based on this principle, has an excellent diagnostic efficiency in 
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identifying stenoses with FFR<0.80, and could be used for intracoronary functional 
assessment when administration of adenosine is not desirable.  
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Table 4.1: Patient demographics 
 
 
Group	  1 Group	  2
Pressure-Flow Pressure only
Stenoses (n) 39 118 157
Age (yr±SD) 64.6±9.9 59.2±16.1 62.6±10.2
Male (%) 35	  (89.7) 98(83.1) 133	  (84.7)
Diabetes (%) 21	  (53.9) 33	  (28) 54	  (34.4)
Smoker (%) 6	  (15.4) 28	  (23.7) 34	  (21.7)
Hypertension (%) 23	  (59) 65	  (55) 88	  (56.1)
Impaired LV function (%) 4	  (10.3) 9	  (7.6) 13	  (8.3)
(EF<50%)
Stable Angina (%) 35	  (89.7) 116	  (98.3) 151	  (96.2)
Unstable Angina (%) 4	  (10.3) 2	  (1.7) 6	  (3.8)
Single Vessel (%) 16	  (41) 92	  (78) 108	  (68.8)
Multi Vessel (%) 23	  (59) 26	  (22) 49	  (31.2)
Coronary Artery (%)
LAD 21	  (54.1) 48	  (40.7) 69	  (44)
Cx 11	  (27) 32	  (27.1) 43	  (27.1)
RCA 7	  (18.9) 38	  (32.2) 45	  (28.9)
Adenosine (route) (%)
Intra-coronary 0	  (0) 96	  (81.4) 96	  (61.2)
Intravenous 39	  (100) 22	  (18.6) 61	  (38.8)
Overall
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Table 4.2: Sub-group analysis 
 
 
Correlation of iFR vs FFR for various sub-groups within the study 
 
 
 Male Age	   Diabetes Hypertension 	  r
(mean	  ±	  SD) IC	  (%) IV	  (%)
Single	  Vessel	  (%) 88	  (81.5) 57.7±16.3 35	  (32.4) 57	  (52.8) 76	  (70.4) 32	  (29.6) 0.89
Multi	  Vessel	  (%) 43	  (87.8) 66.7±8.7 19	  (38.8) 31	  (63.3) 29	  (59.2) 20	  (40.8) 0.92
Coronary	  Artery	  (%)
LAD 59	  (83.6) 62.4±10.3 20	  (28.4) 43	  (61.2) 39	  (55.2) 31	  (44.8) 0.89
Cx 40	  (92.7) 63.3±11.3 18	  (41.5) 27	  (63.4) 21	  (48.8) 22	  (51.2) 0.91
RCA 39	  (88.1) 62.2±8.9 19	  (42.9) 22	  (50) 34	  (76.2) 11	  (23.8) 0.89
Adenosine	  (route)
Intra-­‐coronary	  (%) 77	  (80.2) 60.9±9.7 23	  (24) 49	  (51) 100 -­‐ 0.88
Intravenous	  (%) 54	  (88.5) 65.0±10.3 31	  (50.8) 39	  (63.9) -­‐ 100 0.90
Diabetes	  (%) 45	  (83.3) 63.5±8.0 54	  (100) 40	  (74.1) 23	  (42.6) 31	  (57.4) 0.88
	  
Smoker	  (%) 31	  (91.1) 57.1±10.1 6	  (17.6) 19	  (55.9) 8	  (23.5) 26	  (76.5) 0.85
Hypertension	  (%) 73	  (83) 64.0±9.8 40	  (45.5) 88	  (100) 49	  (55.7) 39	  (44.3) 0.92
Stenoses
88	  (56.1)
Adenosine
108	  (68.8)
49	  (31.2)
70	  (44.7)
43	  (27.3)
44	  (28)
96	  (61.1)
61	  (38.9)
54	  (34.4)
34	  (21.7)
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Figure 4.01: Identification of wave-free period in cardiac cycle 
 
Wave intensity analysis (upper panel) demonstrates the proximal and distal wave 
generated during the cardiac cycle. A wave-free period can be seen in diastole when no 
new waves are generated (shaded). This corresponds to a time period where there is 
minimal distal originating pressure (second panel), minimal and constant resistance 
(third panel) and a near constant rate of change of flow velocity (lower panel).  
Separated pressure above diastole is the residual pulsatile separated pressure 
component after subtraction of the diastolic pressure.  
 
 
 
99 
 
  
Figure 4.02: ADVISE study work flow 
Study Protocol
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Figure 4.03: The reduction in systolic microvascular 
resistance with intravenous adenosine administration 
 
There was a significant fall in the systolic component of 
microvascular resistance (Δ systolic resistance:  461mmHg s/m, 
p<0.001); which was the dominant contributor to the mean fall in 
resistance over the cardiac cycle. 
Change in systolic microvascul r  
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Figure 4.05: Correlation of instantaneous wave-free ratio with FFR 
 
The wave-free period was calculated using a fully automated algorithm.  iFR was 
calculated by dividing mean Pd by Pa during the wave-free period under basal conditions.  
iFR was found to closely agree with FFR (r=0.9, p<0.001).  The dotted lines represent the 
threshold cut-off values for iFR and FFR. 
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Figure 4.06: Diagnostic characteristics of iFR 
 
Receiver Operating Characteristic of iFR. A receiver operation characteristics 
(ROC) curve was calculated using an iFR and FFR as the reference gold-standard 
variable.  The threshold cut-off for FFR was taken as 0.80.  The ROC was found to 
have an area under the curve of 93%, suggesting high accuracy of iFR as a 
diagnostic test.  
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Figure 4.07: C
orrelation and diagnostic characteristics of iFR
 w
ith FFR
 according 
to coronary artery. 
 Left panel, iFR
 at a 0.83 treatm
ent threshold com
pared to FFR
 at a 0.8 treatm
ent threshold. iFR
 
w
as found to correlate closely w
ith FFR
(r=0.9), this w
as consistent in both right (r=0.89, red 
dots) and left coronary arteries (r=0.90, grey dots). R
ight panel iFR
 had a diagnostic accuracy, 
positive predictive value, negative predictive value, sensitivity and specificity of 88%
, 91%
, 
85%
, 85%
 and 91%
 respectively.  This w
as also independent of the coronary artery studied.  
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epeated m
easures analysis of iFR
 and B
land A
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 The baseline pressure data w
as split in half and the iFR
 for each half w
as calculated. The correlation 
of iFR
 1 to iFR
 2 dem
onstrates high reproducibility across the entire range of stenosis severity (left 
panel, m
ean difference betw
een m
easures -0.0005±0.002, p=0.78). The B
land A
ltm
an plot 
dem
onstrates good agreem
ent betw
een iFR
 and FFR
 across the entire range of stenosis severity.    
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Figure 4.09: Schem
atic illustrating the im
portance of m
icrocirculatory (or distal 
originating) pressure in the coronary arteries.  
 In all blood vessel, blood flow
s dow
n a pressure gradient. In the system
ic circulation a pressure 
w
ave is generated follow
ing ventricular contraction travelling from
 the proxim
al to distal end of 
the vessel.  W
hilst m
ost of this w
ave energy travels in an anterograde direction, a sm
all 
proportion is reflected back at site of im
pedance m
ism
atch from
 the distal circulation (upper 
panel). This contrasts w
ith the coronary circulation w
here a pressure w
ave is generated at both 
the proxim
al and distal ends of the vessel, at differing tim
es in the cardiac cycle.  Thus 
intracoronary pressure distal to a stenosis is a com
posite of residual proxim
ally-originating 
pressure and the distal originating pressure from
 com
pression of the intra-m
yocardial vessels.  
iFR
 is calculated during the w
ave-free period in diastole, w
hen distal originating pressure in 
m
inim
ised (Figure 3.02).  The size of the arrow
s pointing in the direction of w
ave travel denote 
the contribution of proxim
al or distal pressure to total pressure, w
ith proxim
al pressure 
predom
inant in the system
ic artery (upper panel) and equal contribution to total pressure from
 
both proxim
al and distal ends in the coronary artery (low
er panel). 
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Figure  4.10: The stability of iFR during haemodynamic 
perturbation  
 
iFR provides a beat-to-beat pressure ratio during the wave-free 
window – comparing each distal pressure with its corresponding 
aortic pressure.  This ensures accuracy regardless of arrhythmia 
(upper panel, ectopy) or variations in blood pressure and heart rate 
(lower panel, tachycardia and respiratory variation in blood 
pressure).  
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5.0  Diagnostic classification of the instantaneous wave-free 
ratio is equivalent to fractional flow reserve and is not 
improved with adenosine administration 
Results of CLARIFY  
(the CLassification Accuracy of pressure-only Ratios against 
Indices using Flow studY) 
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5.1  Abstract 
5.1.1  Background 
The instantaneous wave-free ratio (iFR) is a vasodilator-free pressure-only measure of the 
hemodynamic severity of a coronary stenosis comparable to fractional flow reserve (FFR) in 
diagnostic categorisation. In this study we use hyperaemic stenosis resistance (HSR), a 
combined pressure-and-flow index as an arbiter to determine when iFR and FFR disagree, which 
index is most representative of the hemodynamic significance of the stenosis. We then test 
whether administering adenosine significantly improves diagnostic performance of iFR.  
5.1.2  Method  
In 51 vessels intra-coronary pressure and flow velocity was measured distal to the stenosis 
at rest and during adenosine mediated hyperaemia. iFR (at rest and during adenosine 
administration, iFRa), FFR, HSR, baseline and hyperaemic microvascular resistance were 
calculated using automated algorithms.  
5.1.3 Results 
When iFR and FFR disagreed (4 cases, 7.7% of the study population), HSR agreed with iFR 
in 50% of cases and with FFR in 50% of cases. Differences in magnitude of microvascular 
resistance did not influence diagnostic categorisation; iFR, iFRa and FFR had equally good 
diagnostic agreement with HSR (ROC AUC 0.93 iFR vs 0.94 iFRa and 0.96 FFR, p=0.45).  
5.1.4  Conclusion 
iFR and FFR had equivalent agreement with classification of coronary stenosis severity by HSR.  
Further reduction in resistance by the administration of adenosine did not improve diagnostic 
categorisation, indicating that iFR can be used as an adenosine-free alternative to FFR. 
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5.2  Introduction 
Use of intra-coronary physiological indices to guide revascularisation improves clinical 
outcomes and reduces procedural costs (14-17).  Because of the simplicity of measuring 
intra-coronary pressure and the wealth of outcome data, fractional flow reserve (FFR) is the 
most frequently-used measure of stenosis severity.  However, intra-coronary pressure distal 
to a stenosis reflects not only the severity of the stenosis but also pressure generated from 
the microcirculation (7).  FFR is calculated as a ratio of mean distal to aortic coronary 
pressures over the entire cardiac cycle.  In order to separate the hemodynamics of the 
stenosis from that of the microcirculation, FFR is calculated under conditions of constant 
(and minimal) microvascular resistance (5). This is achieved with the administration of 
vasodilators, such as adenosine (5).  
 
The instantaneous wave-free ratio (iFR) is a pressure-only index that takes an alternative 
approach to the isolation of the hemodynamics of a stenosis from the microcirculation (39). It 
does not use vasodilators; instead it samples intracoronary pressure during the diastolic 
‘wave-free’ period - a period in the cardiac cycle when intra-beat microvascular resistance is 
inherently stable and minimized. This wave-free window provides a phase in which 
microvascular resistance is significantly lower than that over the whole cardiac cycle, and 
coronary hemodynamics are most suited for assessment of the hemodynamic effects of a 
stenosis (12, 39).  However, it is possible that microvascular resistance during the wave-free 
period can be lowered even further with the administration of adenosine and it has been 
suggested that calculating iFR during adenosine administration may improve its ability to 
accurately discriminate flow-limiting stenoses (30). 
 
In the ADenosine Vasodilator Independent Stenosis Evaluation study (ADVISE) the 
classification of stenosis severity was good between iFR and FFR, but, in the absence of a 
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true gold standard, where differences in classification occurred it was difficult to know which 
index was correct.  
 
The absence of a true ischemic gold standard has hampered the development of new 
indices in the past.  Previously, non-invasive imaging modalities have been used to further 
evaluate new intra-coronary physiological tools.  However, these techniques have limitations 
in multi-vessel disease and can only isolate ischemia at the level of a territory rather than a 
specific vessel (44). Therefore, in this study we use the hyperaemic stenosis resistance 
(HSR) index an invasive pressure and flow based index as the reference standard to 
determine which of the pressure based indices most accurately represents the 
hemodynamic severity of the stenosis.  HSR falls back to the fundamental importance of 
simultaneously measuring pressure-flow as first described by Gould and in doing so 
circumvents many of the limitations of a pressure-only index (12).  It is recognised to be 
more stenosis-specific, and less dependent on adenosine mediated hyperaemia than 
pressure-only indices (19-22).  
 
In the first part of this study we compared the diagnostic classification of iFR, iFRa and FFR 
to HSR.  We then assessed the changes in microvascular resistance which occur during the 
three pressure-derived indices to determine how adenosine administration Influences 
diagnostic categorisation. 
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5.3  Methods 
5.3.1 Study population 
This study included 51 stenoses (66.2±9.2 years, 82.7% male) scheduled for coronary 
angiography or PCI at Guys and St Thomas’ NHS Trust, UK or Imperial College London, 
UK. In addition to new data, patients were included from part 1 of the ADVISE study (6). 
Exclusion criteria were limited to significant valvular pathology, previous coronary artery 
bypass surgery and weight >200kg.  All subjects gave written informed consent in 
accordance with the protocol approved by the local ethics committee (NRES 09/H0712/102; 
NCT01118481).  
 
5.3.2 Study Protocol 
Pressure and flow velocity recordings were made distal to the target vessel coronary 
stenosis in 51 vessels at rest and during adenosine-induced hyperaemia (76.5% intra-
venous (140mcg/kg/min) and 23.5% intra-coronary (up to 120mcg).  
 
5.3.2.1 Cardiac Catheterization 
Cardiac catheterization was undertaken through the femoral approach. After diagnostic 
angiography, a 0.014inch pressure and Doppler sensor-tipped wire (ComboWire® XT, 
Volcano Corporation, San Diego, CA) was passed into the target vessel via a guiding 
catheter. Pressure equalisation was performed at the tip of the catheter prior to its 
advancement into the distal vessel. 
 
5000iu unfractionated intravenous heparin was given at the start of the procedure with 
300mcg intracoronary GTN. 
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5.3.2.2 Haemodynamic Recordings 
The EKG, pressures and flow velocity signals were directly extracted from the digital archive 
of the device console (ComboMap®). At the end of each recording the pressure sensor was 
returned to the catheter tip to ensure there was no pressure drift.  Where drift was identified 
the measurements were repeated. An adequate flow envelope was obtained in all patients 
permitting the calculation of flow based indices. Data were analyzed off-line, using a custom 
software package designed with Matlab (Mathworks, Inc, Natick, Mass). 
 
5.3.3 Data Analysis 
 
Processing of digital data (pressure, flow velocity, EKG) for the calculation of the various 
indices was performed at a workstation using Matlab (Mathworks, Inc, Natick, Mass).  iFR 
was calculated as the ratio of distal to proximal pressures over the diastolic wave-free period 
using a fully automated pressure-only algorithm, as previous described (6). This period 
corresponds to a time in the cardiac cycle when waves are absent from the coronary artery 
(6)(Figure 5.01). An instantaneous wave-free ratio following adenosine administration (iFRa) 
was also calculated using the same algorithm. FFR, HSR and basal and hyperaemic 
microvascular resistance were calculated, in all patients, as previously described (14, 15).   
Definition of flow based intra-coronary indices: 
 
Hyperaemic Stenosis Resistance (HSR) =  
!"!!"!  
Hyperemic microvascular resistance (HMR) = 
!"!  
Basal microvascular resistance (BMR) =  
!"!!!  
Wave-free microvascular resistance (wfMVR)=   
!"!"#!!"#  
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𝑃𝑎, mean Aortic Pressure, 𝑃𝑑, mean intracoronary pressure distal to stensosis,  𝑄, mean flow velocity 
distal to stenosis during hyperaemia, 𝑃𝑑! mean intracoronary pressure distal to stenosis at baseline 𝑄!, mean flow velocity distal to stenosis at baseline.  𝑃𝑑!"#/𝑄!"#  distal pressure/ flow velocity over 
the wave free period 
 
5.3.3.1 Statistical analysis 
All data are expressed as mean ± standard deviation or median (25th-75th Quartiles), as 
appropriate.  Receiver operator curves (ROC) were constructed for each index and the 
agreement in diagnostic categorisation was compared between the indices by comparing the 
areas under the ROC using the roccomp command in STATA, version 11, (Statacorp, USA) 
based on DeLong, E. R., D. M. DeLong, and D. L. Clarke-Pearson 1988 (45). The optimal 
cut-off for each of the pressure only indices of iFR, iFRa and FFR were selected to be that 
which maximised the sum of sensitivity and specificity, using HSR as the reference 
standard. The comparison of FFR to HSR was performed at the 0.75 and 0.8 FFR cut off.  
 
We determined the sample variance (probability distribution) of the observed microvascular 
resistance values, of each index, as an estimate of true variance of the entire patient population 
(STATA). The variance of the reduction in resistance for each of the three indices was compared 
using the F-test. A value of p<0.05 was deemed significant. Changes in microvascular resistance 
for each index are compared to cycle averaged resting microvascular resistance 
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5.4  Results 
5.4.1  Patient Distribution 
There was a unimodal left skewed distribution of stenosis severity with 84.3% of stenoses in 
the 0.6-1.0 FFR range, 62.7% of stenoses were in the 0.6-0.9 FFR range (Figure 5.02).   
 
5.4.2  iFR and FFR 
Using a ROC derived iFR cut-point of 0.86 (equivalent to HSR 0.80) there was agreement in 
diagnostic classification between iFR and FFR in 47 out of 51 lesions (92.3%).  In the 4 
lesions in which there was disagreement, in two iFR was negative and FFR positive and in 
the other two iFR was positive and FFR negative (Figure 5.03).  When iFR was negative and 
FFR positive, HSR agreed with FFR in one case and with iFR in the other. In the two cases 
in which iFR was positive and FFR negative, again HSR agreed with FFR in one patient and 
with iFR in the other. In both these cases microvascular resistance during iFR was lower 
than that during adenosine meditated FFR.  
 
iFRa had significantly lower values than FFR and iFR (median iFRa 0.74(0.58,0.85) vs 
median FFR 0.84(0.70,0.89) and median iFR 0.93 (0.83, 0.98) p<0.001 for both). 
Furthermore, this was true for both intra-coronary and intra-venous adenosine 
administration. Despite numerical differences, there was no significance difference in the 
area under ROC curve for either iFR or iFRa when compared to FFR (p=0.15).  
 
Of the adenosine based indices, iFRa provided significantly greater trans-stenotic pressure 
gradients than FFR (iFRa 19.4 (11.2-39.2) mmHg vs 12.2 (7.2-27.9), p<0.001). However, 
iFR produced statistically equivalent trans-stenotic pressure gradients to FFR (iFR 8.2 (3.1-
21.6)mmHg vs 12.2 (7.2-27.9) mmHg, p=0.48).  
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5.4.3 FFR, iFR and iFRa compared to HSR 
The relationship of iFR, FFR and iFRa to HSR was similar (Figure 5.04). Median HSR was 
0.35 (0.19,1.08) mmHg/cm.s. Using the established ischemic cut-off point of greater than 
0.8mmHg/cm.s for HSR (9), a 0.75 cut-off point for FFR was found to have the optimal 
diagnostic efficiency (ROC AUC) of 0.96 (95% CI 0.89-1.0) with a sensitivity of 0.86, a 
specificity of 0.95 and, in this population, a positive and negative predictive value of 0.86 and 
0.95 respectively (Figure 5.05, right panel). This compared to the 0.8 FFR cut-off point which 
had a sensitivity of 0.87, a specificity of 0.84 and a positive and negative predictive value of 
0.68 and 0.94 respectively.  
 
IFRa had an equivalent diagnostic performance to FFR, against HSR as the reference 
standard (ROC AUC 0.94, 95% CI 0.85-1.0, p=0.45 versus FFR, Figure 5.05). 
Corresponding to its numerically smaller values, the classification cut point for iFRa was also 
lower, with a cut point of 0.66 found to have the highest diagnostic efficiency.  With this cut 
point, iFRa had a sensitivity of 0.86, specificity of 0.92 and, in this population, positive and 
negative predictive values of 0.8 and 0.94 respectively.  
 
iFR without adenosine had a diagnostic performance (ROC AUC) of 0.93 (95% CI 0.85-1.0) 
against HSR as the reference standard.  An iFR cut point of 0.86 was found to be equivalent 
of HSR 0.8 (FFR 0.75).  iFR had a sensitivity of 0.86, specificity of 0.95 and, in this 
population, positive and negative predictive values of 0.86 and 0.95 respectively (Figure 
5.04). The relationship of iFR to FFR and HSR was independent of heart rate (Figure 5.06).  
 
There was no significant difference between iFR, iFRa and FFR in terms of agreement with 
HSR guided treatment classification (p=0.48, Figure 5.05).  
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5.4.4 Magnitude of microvascular resistance reduction according to epicardial 
stenosis severity 
 
Intra-coronary microvascular resistance was significantly lower during the diastolic wave-free 
period than averaged values over the whole cardiac cycle at rest (microvascular resistance: 
3.3 (2.07-4.38) mmHg/cm.s vs 5.30 (3.68-7.04) mmHg/cm.s, p<0.001, Figure 5.07).   
 
The relationship between resting diastolic wave-free microvascular resistance and 
hyperaemic microvascular resistance varied according to stenosis severity. In patients with 
physiologically unobstructed arteries, defined as HSR<0.8mmHg.cm/s (36 stenoses, 70.6% 
of the study population) the adenosine based indices of iFRa and FFR demonstrated a 
greater reduction in intra-coronary microvascular resistance (from baseline whole cycle 
microvascular resistance) than that achieved during iFR (FFR: 57.0 (39.7-66.4)% and iFRa 
76.6 (70.3-80.3)% vs iFR 35.8 (30.3-40.6)%, p<0.001 for both, Figure 5.08). Despite the 
lower magnitude of microvascular resistance observed during iFRa and FFR, in this group 
agreement in diagnostic categorisation to HSR was equivalent between the three pressure 
derived indices (diagnostic accuracy = 86.7%).  
 
In patients with physiologically obstructed arteries (HSR>0.8mmHg.cm/s) the fall in 
microvascular resistance was similar during FFR and iFR (FFR: 34.6 (21.0-52.7)% and iFR 
46.4 (32.6-54.3)%, p=0.16, Figure 5.08 & 5.09 right panel), but larger during iFRa (69.2 
(64.5-80.3)%, p<0.001 compared to both FFR and iFR).    
 
5.4.5 Microvascular resistance during the resting wave-free period can be 
lower than microvascular resistance during hyperaemic whole cycle 
microvascular resistance  
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In 39% of stenoses (20 stenoses, range 0.35-0.99), over both physiologically unobstructed 
and obstructed vessels (range 0.35-0.99), microvascular resistance was not lower during 
adenosine mediated FFR compared to that during the baseline iFR wave-free period (Figure 
5.09). In this group median FFR was 0.79 (inter-quartile range=0.28) compared to a median 
iFR of 0.84 (inter-quartile range=0.35).  This phenomenon of lower microvascular resistance 
during iFR occurred in 34.4% (11 stenoses) in the 0.6-0.9 FFR range. 
 
5.4.6 Comparison of iFR and FFR in the 0.6-0.9 FFR range 
62.7% of stenoses fell within the 0.6-0.9 FFR range. In this range, both iFR and FFR had 
identical diagnostic agreement with HSR, 87.5%. Diagnostic agreement of iFRa to HSR was 
84.4%. The sensitivity of iFR, FFR and iFRa was 66.7% for all. The specificity of iFR, FFR 
and iFRa was 92.3%, 92.3% and 88.5% respectively (Figure 5.10). 
 
When microvascular reduction (compared to baseline whole cycle microvascular resistance) 
is plotted according to stenosis severity (Figure 5.11) it can be seen that the reduction in 
microvascular resistance during the wave free period increases with increasing epicardial 
stenosis severity (Figure 5.11, right panel). The opposite was true with FFR where the 
magnitude of reduction in microvascular resistance was lower in vessels with more severe 
stenoses (Figure 5.10, left panel). 
 
5.4.7 Consistency of microvascular resistance reduction achieved during iFR, 
FFR and iFRa 
Across the entire stenosis range, adenosine mediated FFR had a more heterogeneous 
effect on microvascular resistance than the wave-free period (37.2% (inter-quartile range 
15.8%) reduction in microvascular resistance during iFR vs 53.9% (inter-quartile range 
29.0%) during FFR, F-test, p<0.001), (Figure 5.10, upper panel). This was particularly true of 
the 0.6-0.9 range (37.2% (inter-quartile range 12.6%) reduction in microvascular resistance 
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during iFR vs 55.7% (inter-quartile range 34.9%) reduction in microvascular resistance 
during FFR, F-test, p<0.001))(Figure 5.10, upper panels – red dots). 
The reduction in microvascular resistance during iFRa was more consistent than that during 
FFR (microvascular resistance reduction during iFRa 75.6% (inter-quartile range 12.3%) vs 
median microvascular resistance reduction during FFR 53.9% (inter-quartile range 29.0%), 
F-test, p<0.001). Despite microvascular resistance reduction during iFRa being numerically 
greater than that during iFR (microvacular resistance reduction durng iFRa 75.6% (inter-
quartile range 12.3%) vs microvascular resistance reduction duing iFR 37.2% (inter-quartile 
range 15.8%), p<0.001), micorvascular resistance reduction during iFR was just as 
consistent as that during iFRa (F test, p=0.73). Furthermore, this was true in the 0.6-0.9 FFR 
range (iFR inter-quartile range 12.6% vs iFRa inter-quartile range 11.8%, F-test, p=0.10). 
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5.5  Discussion 
In this study we found that: 1) iFR and FFR have equal diagnostic classification agreement 
with HSR, 2) reduction in microvascular resistance during iFR is more consistent than that 
achieved during adenosine mediated FFR 3) microvascular resistance reduction during iFR 
is higher with increasing stenosis severity whilst the opposite is true for FFR and 4) despite 
resistance being lower when iFR is measured following administration of adenosine (iFRa) 
this does not improve classification agreement with HSR.   
 
5.5.1  iFR and FFR have equivalent agreement with HSR across the entire 
stenosis range 
The equivalent diagnostic performance of iFR and FFR are consistent with the findings of 
three other studies, including more than 800 stenoses: ADVISE (25), ADVISE-Registry (46) 
and the South Korean prospective blinded study (47).  Importantly, in all these studies the 
same automated algorithm for calculation of iFR was used. However, when iFR was 
calculated using a different investigator-designed algorithm, in the VERIFY study, a weaker 
correlation between iFR and FFR was reported (43).  Furthermore, VERIFY suggested that 
resistance could made lower over the wave-free period following adenosine administration 
perhaps leading to improvement in stenosis discrimination.   
 
It has been accepted that iFR and FFR have excellent agreement at the extremes of 
stenosis severity. However, since the publication of ADVISE there has been much 
speculation with regard to the scatter in correlation plot between iFR and FFR in the 0.6-0.9 
range. Despite the fact that FFR itself has not been validated extensively in this intermediate 
range (46, 48, 49) this disagreement has been attributed by some as a limitation of iFR (30).  
Our findings suggest that hyperaemic whole cycle microvascular resistance is far more 
variable than resting wave-free microvascular resistance and that this variability is maximal 
in the intermediate range of stenosis severity (Figure 5.10); a finding consistent with those of 
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others (18).  This suggests that this biological intrinsic FFR variability may be the principle 
driver of differences between iFR and FFR.  This variability in microvascular resistance 
during adenosine administration is likely to occur due to variability in adenosine mediated 
responses of the myocardium and microvasculature (50, 51). The more consistent reduction 
in microvascular resistance during iFR and iFRa compared to FFR suggests the 
predominant cause of the variable effect of adenosine on coronary microvascular resistance 
occurs during systole and early diastole – active phases of the cardiac cycle that are 
excluded by the wave-free window (25). This is consistent with the seminal work of Gould 
which demonstrated that the pressure drop across a stenosis can be assessed most 
reproducibly during a period in the cardiac cycle free of the confounding effect of active 
contraction and relaxation of the myocardium on intra-coronary pressure (systole and early 
diastole) (12, 25). 
 
In terms of FFR this manifests clinically as the cause of disagreement in repeated measures 
of FFR in the same lesion. Consequently the test re-test agreement of FFR in the 0.6-0.90 
range, based on the DEFER reproducibility dataset where FFR was measured twice 10 
minutes apart, is not 100% but only 81% (46). Therefore when iFR and FFR disagree in this 
range it is not certain that a repeated measure of FFR will even agree with itself. Indeed, 
stenoses in this range were never explored with the same power as those at the extremities 
of severity in the ischemia validation studies of FFR. As a result, it is possible that this may 
be an inherent limitation of using FFR as a reference standard in this range (46, 47).  
 
By measuring both pressure and flow HSR is less susceptible to the heterogeneous 
response to adenosine (37-40). When used as the reference standard in this range, our 
results demonstrate equivalent diagnostic categorisation of iFR and FFR (Figure 5.09). 
Given these findings it is reasonable to speculate that FFR, with its significantly more 
variable microvascular resistance reduction in the 0.6-0.9 range, is the predominant 
contributor to the scatter in this region (Figure 5.10).  
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A simple post hoc restricted correlation analysis between iFR and FFR in a limited range of 
FFR values (such as 0.6 to 0.9) can be misleading, especially when the intrinsic variability of 
FFR is not taken into account (14, 46).  A more robust method of further characterising the 
diagnostic accuracy of iFR in this range is to prospectively identify a study population rich in 
lesions around this range. To this end the ADVISE Registry (339 patients) and the South 
Korean Registry (238 patients) were designed to answer this question (46, 47). To the best 
of our knowledge, these were the first studies to ever assess FFR in a distribution similar to 
that seen in routine clinical setting (80% lesions in 0.6-0.9 range). Reassuringly, when 
accounting for the inherent variability of FFR in this range, these studies also demonstrated 
close categorisation match between iFR and FFR. 
 
5.5.2 How can greater reduction of intracoronary microvascular resistance not 
give greater diagnostic value? 
 
Pressure derived indices rely on Ohm’s law which demonstrates that a pressure gradient 
(∆𝑃) is equal to the product of flow (𝑄) and resistance (𝑅) (∆𝑃 = 𝑄𝑅). Therefore, for a 
pressure gradient to be used as a surrogate for flow, intracoronary microvascular resistance 
simply needs to be stable.  However, to provide a clinically useful index, microvascular 
resistance also needs to be low enough, and flow high enough, to discriminate between 
trans-stenotic pressure gradients and therefore permit the index to differentiate between 
stenoses of differing severity.  This has led to the current dogma which suggests that ever 
greater reductions in microvascular resistance should lead to an improvement in 
classification agreement (43).  However, our results indicate that iFR, FFR and iFRa had 
equivalent agreement in diagnostic classification with HSR. This observation is in keeping 
with other recent independent studies, which have also shown that diagnostic categorisation 
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agreement is not necessarily improved after the administration of pharmacological 
vasodilators (52).  
 
From our results, the lack of incremental diagnostic benefit of the hyperaemic indices of 
iFRa and FFR is because of two principle reasons.  
 
1. Microvascular resistance reduction in FFR varies according to stenosis severity 
 
During FFR, adenosine mediated reduction in microvascular resistance was most marked in 
patients with physiologically unobstructed arteries (as defined by HSR) (Figure 5.08). In 
these patients the reduction in microvascular resistance was significantly greater than that 
during iFR (Figure 5.09, shaded area left panel). This is simply a reflection of the effect of 
auto-regulation which keeps coronary flow constant (18); as stenoses get progressively 
more severe the microvasculature dilates to ensure adequate flow to the myocardium. 
Consequently, the effect of adenosine in arteries with severe lesions is limited as the 
microcirculation has little scope to dilate further when adenosine is administered - they have 
limited vasodilator reserve. However, the effect of adenosine in arteries with mild lesions is 
much greater as the microcirculation is relatively vasoconstricted and as a result the 
vasodilator reserve of these arteries is much larger. These findings are consistent with 
previous observations demonstrating an inverse relationship between adenosine mediated 
vasodilator reserve of a coronary artery and epicardial stenosis severity (18, 53).   
 
Therefore when there is a significantly greater reduction in microvascular resistance during 
FFR, as compared to iFR, it does not impact on diagnostic accuracy because it occurs in the 
physiologically least obstructive cases (which are so far from the ischemic cut-off point that 
they are anyway correctly classified). These cases of physiologically unobstructed arteries 
contrast markedly with those patients with significant obstructive coronary disease.  In cases 
of physiologically significant coronary disease (HSR>0.8) the magnitude of microvascular 
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resistance reduction achieved by adenosine during FFR is far lower (Figure 5.08, ‘whole 
cycle adenosine’) and microvascular resistance during iFR is equivalent to that during FFR, 
and in some cases even lower (Figure 5.09, left panel unshaded area).  
 
2. Reduction in microvascular resistance during the wave-free period is sufficient to 
differentiate between stenosis severities 
 
Microvascular resistance reduction during iFRa was consistently greater than that possible 
during iFR and FFR.  Despite this, diagnostic accuracy of iFRa was not improved even in the 
clinically relevant 0.6-0.9 FFR range. This suggests that the natural increase in coronary 
flow velocity and reduction in microvascular resistance during iFR is sufficient in magnitude 
to assess the fluid dynamics of a stenosis and to accurately differentiate according to 
severity without the need for adenosine.  
 
These two observations question the need for "maximal flow" in stenosis assessment. 
Indeed, for any apparent-maximal flow achieved with one dose of one vasodilator, that with 
another dose or drug might be different (54). Moreover, even setting aside pharmacological 
considerations, for any maximal flow achieved over the whole cardiac cycle, the flow in 
diastole may be higher and that during the wave-free period higher still.  Since the increases 
in flow will not be exactly identical between methods, the pressure drops will also not be 
identical, and the methods will have some degree of numerical disagreement reflected in 
their different cut points. But, as this study finds, the indices will not necessarily differ in their 
diagnostic discrimination, provided the increase in flow is sufficient, consistent and 
microvascular resistance remains stable. Thus, instead of chasing the potentially 
unachievable state of “maximal” hyperaemia, isolating an intrinsically stable resistance 
phase of the cardiac cycle, the diastolic wave-free period, provides a mechanism to obtain a 
flow that is consistently high enough, for the accurate assessment of a stenosis. 
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5.5.3 Why microvascular resistance during the wave-free period can be lower 
than that during FFR 
In approximately 40% of stenoses microvascular resistance during the wave-free period was 
lower than that over the complete cardiac cycle during adenosine mediated FFR.  This 
phenomenon occurred across the entire range of stenosis severities, including 
approximately one third of stenoses in the 0.6-0.9 FFR range.  In practice, this means that in 
a significant proportion of patients, adenosine mediated FFR fails to increase flow greater 
than that already present at baseline during the diastolic wave-free period. This has 
previously only been described in a small minority of cases when comparing resting whole 
cycle microvascular resistance to hyperaemic whole cycle microvascular resistance (FFR) 
(55).  
 
There are several potential reasons why the proportion of stenoses in this study 
demonstrating this phenomenon is larger than that previously described.  Firstly, in contrast 
to previous studies documenting this phenomenon this study used predominantly 
intravenous adenosine.   This enables measurements to be made in more severe lesions, 
where the operator has more time to attain a good Doppler trace.  This is often far harder 
using intra-coronary adenosine, where the increase in flow velocity following adenosine 
administration is more transient and therefore the time window to achieve a good Doppler 
envelope is far shorter.  Secondly, the larger proportion of stenoses with this paradoxical 
response may also reflect the unique hemodynamics of the wave-free period.  Phasic 
analysis of coronary pressure, flow and microvascular resistance demonstrates that 
microvascular resistance is approximately 30-40% lower during the wave-free period when 
compared to whole cycle microvascular resistance.  Consequently adenosine mediated FFR 
microvascular resistance is required to be consistently lower to surpass the reduction in 
microvascular resistance already achieved by simply selecting the wave-free period. 
Unfortunately, the variable reduction in microvascular resistance during FFR (18) prevents 
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this from being consistently achieved and it is not possible to predict, in advance, in which 
patients this will occur.  By obviating the need for vasodilator administration iFR is not 
subject to the natural variability associated with drug administration between patients and 
therefore provides a more consistent assessment across lesions of similar severity (Figure 
5.10). 
 
5.6 Study limitations 
Whilst we use HSR as the reference standard in this study it should be noted that there is no 
gold standard ischemia test. Whilst this is an inherent limitation to the establishment of any 
new ischemic test we chose HSR as the reference standard because it measures both 
pressure and flow and is therefore less susceptible to the heterogeneous effect of adenosine 
and because of its high specificity for ischemia (19-22).  
 
The iFR cut point of 0.86 in this study is different to that in the ADVISE study (25). This is 
because in this study we compare iFR to the ischemic cut-off points of HSR (0.8) and FFR 
(0.75).  It should be noted that this is different to the ADVISE-Registry (46) and the Korean 
study (47) which were both highly powered to assess the cut-point relating to the clinical 
(non-ischemic) FFR cut-off of 0.8.  Their findings were consistent with 0.89 being equivalent 
to FFR 0.8. In this study the HSR 0.8 cut off is equivalent to FFR 0.75, and as such, it was 
necessary to obtain the iFR value (0.86) pertaining to these values.    
 
This is a small study compared to the larger pressure-only studies in this field. As with all 
mechanistic studies interpretation of our findings should be done in the context of the study 
size. However, this remains one of the largest pressure and flow studies using intravenous 
adenosine, and the only study comparing FFR, iFR and HSR in the 0.6-0.9 range. The 
number of patients in which iFR and FFR disagree with each other is small and their 
significance should be interpreted with caution.  However, it should be noted that the 
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proportion (7.7%) is consistent with clinical populations, ADVISE Registry (6%) and South 
Korean Study (6%), suggesting that the study findings are consistent with other, larger 
datasets (46, 47). 
 
The distribution of stenoses in this study is unimodal with leftward skew, which is more 
reflective of the distribution seen in routine clinical practice (46, 47). It may be argued that 
the skew towards normal may have masked any potential differences between iFR and the 
hyperaemic indices.  However, rather than acting in favour of iFR such a skew is more likely 
to place iFR at a disadvantage, particularly if the magnitude of microvascular resistance is a 
key discriminator between the diagnostic accuracy of iFR and FFR as is assumed. This is 
because in a population such as this, the skew towards normal identifies a population with 
marked differences in microvascular resistance between iFR and FFR.  Given that 
reductions in microvascular resistance with hyperaemia are most marked in patients with 
less obstructive lesions one would expect the agreement of iFR to FFR and HSR to be weak 
in such a population and therefore biased against iFR. The fact that the level of agreement 
between indices is good (including the 0.6-0.9 range) suggests that our conclusions that the 
flow velocity achieved during the wave-free period is sufficient to assess a stenosis and 
pharmacologically induced greater flow is surplus to requirement is valid. Therefore, rather 
than introducing bias, the good level of agreement in this data distribution should reassure 
clinicians that the principal physiological findings of this study are applicable to the patients 
that they see in the catheterisation laboratory.  
 
The ability to measure flow velocity accurately is challenging and has the potential to 
introduce a source of error. However, this was limited as measurements were made with 
intravenous adenosine to ensure adequate time was available to achieve the best possible 
flow velocity envelope and performed by experienced operators well practiced at making 
flow measurements. To this end it is reassuring that our resistance findings are consistent 
with that reported by others (18). 
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5.7  The next step for iFR 
Physiologic guided revascularisation has been demonstrated to improve clinical outcomes 
and reduce procedural costs (1, 2). However adoption into clinical practice has been limited 
(56). One of the reasons for this is the requirement of adenosine (56, 57).  As a vasodilator 
independent index iFR has been proposed as a possible solution to this problem. Given the 
good categorisation match with FFR in over 800 stenoses to date it can be argued that there 
is little to gain from further comparisons with FFR.  Furthermore, by measuring flow we 
identify a physiological reason that questions the use of FFR as the reference standard 
particularly in the 0.6-0.9 range – the variable response to adenosine.  Whilst we find that 
iFR is equivalent to FFR at detecting hemodynamic significant stenoses (as defined by HSR) 
the true measure of the clinical utility of the index will be determined by outcome studies. To 
this end a systematic appraisal of iFR guided deferral of therapy would allow clinicians to 
begin to assess its place in the clinical domain.  
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Table 5.1: Patient Demographics 
 
 
 
 
Stenoses, %(n)
Male 82.4(42)
Age 66.2±9.2
Risk Factors
Smoker 29.4(15)
Diabetic 27.4(14)
Hypertension 35.2(18)
Family History 25.5(13)
Vessel
LAD 56.8(29)
Cx 21.6(11)
RCA 21.6(11)
Adenosine Route
IV 76.5(39)
IC 23.5(12)
Stenosis Severity
(-) HSR 70.6(36)
(+) HSR 29.4(15)
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Figure 5.01: Wave intensity during the diastolic 
‘wave-free’ period.  
 
Representative traces showing coronary artery wave 
intensity (upper panel) and corresponding pressure 
waveform (lower panel). The duration of diastole and the 
diastolic wave-free period are indicated with dashed 
vertical lines. The portion of the pressure waveform used 
to calculate the instantaneous wave-free ratio (iFR) in this 
study is highlighted in green. 
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Figure 5.02: Frequency distribution of Fractional 
Flow Reserve (FFR) values in study. 
 
It can be seen that a significant proportion (62.7%) of the 
stenoses are in the 0.6-0.9 range. 
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Figure 5.03: iFR and FFR disagreements 
 
iFR and FFR disagreed in 4 stenoses in terms of treatment categorisation. 
When this occurred HSR agreed with iFR in 50% of cases and FFR in 
50% of cases. 
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Figure 5.04: Relationship 
of iFR, FFR and iFRa to 
HSR 
 
All three pressure derived 
indices have an inverse 
numerical relationship with 
HSR. As stenosis resistance 
increases the pressure derived 
indices decrease in value. 
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Figure 5.05: D
iagnostic characteristics of iFR
, iFR
a and FFR
 using H
SR
 as the reference 
standard.  
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Figure 5.06: The influence on heart rate on agreem
ent of iFR
 w
ith FFR
  
 It can be seen that w
hen the difference betw
een iFR
 and FFR
 cannot be explained by patient 
heart rate. 
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Figure 5.07: Flow
 velocity, pressure and instantaneous m
icrovascular resistance 
during the w
ave-free period com
pared to that of the cardiac cycle under resting 
conditions.  
 The percent difference betw
een m
easures calculated over the w
ave-free period and the entire 
cardiac cycle are show
n (values are expressed as m
edian±IQ
R
).  
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Figure 5.08: R
eduction in m
icrovascular resistance according to epicardial 
stenosis severity 
 A histogram
 com
paring the m
agnitude of m
icrovascular resistance reduction in each of the 
three pressure based indices to that of the com
plete cardiac cycle under resting conditions.  
M
icrovascular resistance reduction is consistent w
ith iFR
 and iFR
a in vessels w
ith 
significant and non significant stenosis. H
ow
ever, w
ith FFR
 m
icrovascular resistance 
reduction is significantly low
er in vessels w
ith significant stenoses. 
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Figure 5.09: iFR vs FFR Reduction in m
icrovascular resistance according to epicardial stenosis 
severity 
 A plot of difference in m
icrovascular resistance betw
een iFR
 and FFR
 against stenosis severity according to H
SR
.  
It can be seen that w
hen FFR
 m
icrovascular resistance is significantly low
er than that during iFR
 it invariably 
occurs in vessels w
ith non significant stenoses, As stenosis severity increases this difference falls, such that 
m
icrovascular resistance during iFR
 and FFR
 in significant stenoses are equivalent (p=0.50), right panel. In 39%
 
of stenoses iFR
 m
icrovascular resistance w
as low
er than that during FFR
 and this w
as not confined to severe 
lesions. (G
reen bar=negative H
SR
)  
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  Figure 5.10: C
om
parison of diagnostic characteristics of iFR
, FFR
 and iFR
a in 
stenoses in the 0.6-0.9 FFR
 range  
 iFR
 and FFR
 have equivalent diagnostic characteristics w
hen com
pared to H
S
R
 diagnostic 
categorisation in the 0.6-0.9 FFR
 range 
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R
 is close to a value of 1 m
icrovascular resistance over the w
ave-free period is 
consistently low
er than that during the w
hole cycle at rest. A
s stenosis severity increases the 
reduction in m
icrovascular resistance during the w
ave-free period increases suggesting that 
the autonom
ic system
 causes m
icrovascular dilatation in order to m
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 as epicardial 
stenosis severity increases. In contrast adenosine m
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resistance. F
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ilar grade in stenosis its effects on m
icrovascular resistance are far m
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varied. F
urtherm
ore as stenosis severity increases the ability of adenosine to increase flow
 is 
reduced.  
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6.0 Synthesis 
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In this series of studies I have identified a period in the cardiac cycle that provides 
the most appropriate widow for the pressure only assessment of a coronary stenosis 
– the diastolic wave-free period. During this period microvascular resistance is as 
stable as that induced during adenosine mediated fractional flow reserve and intra-
coronary pressure is free of the confounding effect of the contracting and relaxing 
myocardium distally. The trans-stenotic pressure ratio measured during this window 
at rest provides similar stenosis classification to fractional flow reserve. Furthermore 
the ability of iFR to correctly classify stenoses is not improved with the administration 
of adenosine; suggesting that the flow velocity increase during this window is 
sufficient for stenosis discrimination.  
 
This series of studies challenge the current dogma that hyperaemia is absolutely 
necessary for stenosis assessment. As a result several of the findings in these 
studies deserve closer discussion in the context of pre-existing data in the literature.  
 
6.1 Whole cycle or phasic analysis? 
 
‘The purely fluid dynamic character of the stenosis, [that is] the pressure gradient-
velocity relationship of the stenosis without the extraneous effects of deceleration 
and acceleration,..’          
      KL Gould, Circulation Research 1978 (12) 
 
Separate from the discussion with regard to the need for hyperaemic agents the 
period of the cardiac cycle most appropriate for the haemodynamic assessment of a 
coronary stenosis has been investigated by others over the last 30 years. In a 
seminal study by Gould in 1976, in the canine model (12), he elegantly demonstrated 
the importance of assessing stenosis severity during a period in the cardiac cycle 
when intra-coronary pressure and flow velocity are free of the confounding effects of 
  143 
the contracting and relaxing myocardium. Using separate pressure and Doppler 
tipped wires and manual post hoc analysis of the data Gould demonstrated that 
stenoses could be differentiated according to severity at rest. Furthermore, he 
determined that the trans-stenotic pressure gradient had a curvilinear relationship 
with flow velocity – fitting the relationship ΔP=Fv+Sv2. This seminal work was 
followed several years later by that of Marques et al (56, 57). They derived a new 
pressure and flow velocity derived index that used the pressure gradient flow velocity 
at the mid point of diastole using the onset of adenosine mediated hyperaemia to 
create curves similar to that of Gould. They then extrapolated their curves to a 
velocity of 50cm/s to derive a pressure gradient. This pressure gradient at fixed 
velocity (dpv 50) was found to provide a more accurate assessment of ischemia than 
fractional flow reserve (28). However, there were several limitations to this index. 
First, it required simultaneous pressure and flow velocity measurements, which was 
not possible until the introduction of the Combiwire in 2006. Therefore the 
investigators were forced to make measurement with separate pressure and Doppler 
tipped wires adding time and complexity to the procedure. Second, interpretation of 
the data required extensive post hoc manual analysis of the data. Finally, in a 
significant proportion of patients the traditional curves could not be constructed. As a 
result despite the clear physiological advantages of this index it was not clinically 
adopted.  
 
Around about the same time Abe et al. (41) derived the hyperaemic diastolic 
fractional flow reserve. This isolated diastole according to the LV pressure wave-form 
and therefore required a catheter in the left ventricle. The resulting index was found 
to be superior to FFR in determining stenosis severity. However, once again its 
measurement was more complicated than FFR - limiting its clinical adoption.  
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Despite the clinical impracticality of the DpV50 and diastolic FFR they both 
demonstrated that it was possible to use phasic rather than whole cycle averaged 
haemodynamics to assess stenoses in humans and more important when this is 
done the resultant index is more accurate than whole cycle indices.  
 
Wave intensity analysis integrates the changes in pressure and flow velocity at each 
point in the cardiac cycle to determine the predominant determinant of coronary flow. 
It is therefore the ideal tool to identify a period in the cardiac cycle when the effect of 
the dynamic myocardium is minimized – the wave-free period. Using traditional 
pressure and flow velocity analysis I demonstrate that this period is in fact 
synonymous with the period defined by Gould in 1978 in the canine model. Our 
approach, derivation of the pressure gradient flow velocity loop and identification of 
diastole has important distinctions with that of the work of Marques and Abe. First the 
derivation of these curves did not require the administration of adenosine but simply 
the natural pressure and flow velocity changes that occur throughout diastole. As a 
result the curves are independent of the heterogeneous effects of adenosine. 
Second, the curves were constructed using automated algorithms permitting more 
rapid construction. Third the onset of diastole was defined by using the aortic 
pressure trace rather than the LV pressure wave-form obviating the need for a 
catheter in the left ventricle. Most importantly, whilst the advantages of measuring 
stenosis severity during a period in the cardiac cycle free of the confounding effect of 
the myocardium was previously documented, by using modern high fidelity pressure 
and flow wires and computational power, we are the first to isolate such a period in 
real time in a fully automated manner. Furthermore, we make an incremental step by 
using pressure alone over this period to determine stenosis severity. Consequently, 
contrary to prior investigators, we have derived an index over this window that can be 
easily adopted into clinical practice.  
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6.2  The effect of adenosine on microvascular resistance according to 
stenosis severity 
ADIVSE demonstrated that microvascular resistance during the diastolic wave-free 
period was as stable as that provided by adenosine mediated fractional flow reserve. 
It also demonstrated that the magnitude of resistance was similar to that induced by 
adenosine during FFR. Whilst the former finding has not been disputed the latter 
finding has caused much controversy in the field (31, 32). It can be explained, 
however, by taking into account the differential effect of adenosine on microvascular 
resistance according to stenosis severity.  
 
Uren and Colleagues in 1994 (18) used PET to demonstrate that the effect of 
adenosine varied according to stenosis severity. In patients with unobstructed 
coronaries flow was markedly enhanced by the administration of adenosine. 
However, as stenosis severity increased the effect of adenosine diminished, such 
that its effect on flow was minimal in the 50-90% stenosis range (as defined by QCA). 
Furthermore, they demonstrated the marked heterogeneous effect of adenosine 
between patients with similar stenosis severities. These finding can be used to 
explain the discrepancies between the microvascular resistance findings of ADVISE 
and CLARIFY.  
 
In CLARIFY, in patients with non flow limiting disease (HSR<0.8) I demonstrated that 
microvascular resistance values were on average significantly lower than that 
possible over the resting wave-free period. However, in patients with flow limiting 
disease (HSR>0.8) I demonstrated that microvascular resistance over the wave-free 
period was similar and in some cases much lower than that possible during 
adenosine medicated FFR. The resistance comparison between iFR and FFR is 
therefore acutely sensitive to the composition of stenoses in the patient population. If 
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there is a predominance of mild stenoses hyperaemic microvascular resistance will 
be much less than resting wave-free resistance. In contrast a higher proportion of 
severe lesions may mean that microvascular resistance between the two indices is 
similar. Whilst it is clear that wave-free resistance is not always similar to that 
achieved during adenosine mediated FFR the diagnostic implications of this finding 
appears to be minimal as the cases in which there are large disparities between the 
two indices are so far away from the treatment cut point that clinical categorization 
remains unchanged. This is confirmed by the findings of CLARIFY. 
 
6.3  Rest flow, ‘maximal’ flow or will somewhere in between suffice? 
 
‘A direct relation between coronary pressure and flow, however, may only be 
presumed if the resistances in the coronary circulation are constant (and minimal) as 
theoretically is the case during maximum arteriolar vasodilation’ 
NH Pijls et al Circulation 1993(5) 
 
Adenosine administration did not necessarily reduce microvascular resistance. 
Adenosine had a more consistent effect when systole was excluded. For example, 
the administration of adenosine in the context of FFR was associated with a highly 
variable response; with approximately 40% of patients having lower microvascular 
resistance over the resting diastolic wave-free period. This was not true for iFRa. 
Adenosine administration during the wave-free period provided a consistently greater 
reduction in microvascular resistance than that possible during iFR and FFR. 
Furthermore, this effect did not appear to be as sensitive to stenosis severity as FFR. 
Traditional teaching would suggest iFRa should therefore provide a more accurate 
measure of ischemia as microvascular resistance is minimized further. However, 
despite the significantly lower distal to proximal pressure ratio of iFRa it was not 
  147 
found to afford better diagnostic accuracy than FFR or even the resting index of iFR. 
These finding can be explained by using the original Gould pressure gradient flow 
velocity curves. The higher flow velocity simply pushes the pressure gradient along 
the same curve therefore whilst the pressure gradient is lower the stenosis does not 
change treatment classification/ severity as the increased flow velocity is taken into 
account with a lower treatment threshold 0.66 for iFR vs 0.75 for FFR.   
These findings have significant implications for adenosine mediated fractional flow 
reserve. A stipulation of FFR is the need to assess stenosis severity at maximal flow 
and therefore minimal (and constant) microvascular resistance in the subtended 
artery. However, as others have demonstrated with ever increasing doses of 
adenosine, the addition of alpha blockers, sodium nitroprusside or ACE inhibitors - 
flow in the coronary can be increased further than that possible with 140mcg/kg/min 
of adenosine. Furthermore regardless of the drug or combination of drugs flow will be 
higher during diastole and higher still during the wave-free period –questioning the 
feasibility of ever obtaining maximal hyperaemia.  
 
However, these findings do not negate the role of FFR; the FAME (16) and FAME II 
(17) studies used adenosine at a dose of 140mcg/kg/min and demonstrated clear 
clinical benefits. But they do challenge the stipulation that flow needs to be maximal 
for the accurate assessment of a coronary stenoses. This suggests that 
microvascular resistance during pressure only assessment of coronary stenoses 
needs to satisfy two conditions: 
1. Sufficiently stable so trans-stenotic pressure can be used as a surrogate for flow 
and 
 2. Low enough to permit accurate discrimination between stenoses of differing 
severities 
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The equal diagnostic categorization of iFR, FFR and iFRa suggest that microvascular 
resistance during the resting diastolic wave-free period satisfies these requirements 
and further pharmacological reduction is perhaps surplus to requirement.  
 
6.4  Estimating true underlying flow – should we use resting pressure 
or hyperaemic pressure? 
It is assumed that hyperaemic pressure provides a more accurate refpection of true 
underlying flow. However, the literature does not support this view. The effect of 
vasodilatation on stenosis geometry and the relationship of trans-stenotic pressure 
gradient, flow velocity and flow volume were described in detail by Gould and Kelly 
(58). In this study, in the canine model, they demonstrated that the pressure gradient 
flow velocity relationship and pressure gradient flow volume relationship were 
identical at rest. They went onto demonstrate that this was not the case during 
hyperaemia. During hyperaemia there was a clear divergence between the pressure 
gradient-flow volume curves and pressure gradient flow-velocity curves; with the 
latter overestimating the true pressure gradient-flow volume curves.  
 
If this over estimation was consistent and predictable then it could be accounted for 
unfortunately this is not the case and therefore during hyperaemia whilst trans-
stenotic pressure may be proportional to flow velocity it may not be proportional to 
true flow.  
 
These findings suggest that provided flow velocity is high enough to provide 
adequate sensitivity (as is true of the wave-free period) the resting pressure gradient 
provides an accurate assessment of true underlying flow within the vessel and the 
absence of vasodilatation does not under-estimate the true effect of the stenosis on 
coronary flow volume.  
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The wave-free period provides flow velocity that is high enough along the resting 
pressure gradient flow velocity curve to permit accurate discrimination between 
stenoses but also by remaining on the resting curve may perhaps provide a more 
accurate assessment of true underlying flow. This hypothesis will be investigated in 
future studies.  
 
6.5  Limitations of no gold standard 
 
The development of any ischemia test is limited by the lack of a gold standard. Whilst 
fractional flow reserve has been advocated as the gold standard ischemia test it has 
clear limitation in the context of microvascular function – highlighted by the 30% 
discordance rate between CFR and FFR. 
 
Furthermore, the ability of FFR to agree with itself is limited.. There has been much 
speculation about the scatter of patients in the correlation of iFR to FFR in ADVISE 
(58, 59). We were surprised that the poor correlation in this zone was so readily 
attributed to iFR given the well documented large variance in flow during hyperaemia. 
Indeed Gould in 1974 demonstrated that hyperaemic flow is significantly more 
variable than resting flow (59). This is substantiated by the test-re-test agreement of 
FFR in this range of only 81% in the DEFER study (14). As a result when iFR and 
FFR disagree in this range it is not clear if a repeated measure of FFR would in fact 
agree with its first measurement. Therefore it is difficult to understand why scatter in 
this range is so readily attributed to iFR as opposed to that of the hyperaemic index 
(i.e. FFR) with a far larger variance.  
 
This is further confounded by the limited data on FFR in the in the range straddling 
the 0.75 cut point.  In the two seminal papers comparing FFR to non-invasive tests 
the proportion of patients in this range was limited. In the New England Journal paper 
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of 1996 (49) only 53.0% of lesions were between 0.6-0.9 where as in the PET study 
of 1994 (48) there were only 32.8% of lesions in this range. In this respect CLARIFY, 
which includes 62.7% of lesions in this range, represents one of the largest flow 
based studies comparing FFR to ischemia (HSR) to be performed in 0.6-0.9 range. 
Despite this, the numbers of patients are small so a post hoc restricted analysis of 
the correlation of iFR to FFR in this range that does not account for the inherent 
variability of FFR may produce misleading results (60).  
 
A more robust method of further characterising the diagnostic accuracy of iFR in this 
range is to prospectively identify a study population rich in lesions around this range. 
To this end the ADVISE-Registry (46) and the South Korean Registry (47) were 
designed to answer this question.  Surprisingly, these were the first studies to ever 
assess FFR in a distribution similar to that seen in a clinical setting, with 80% of the 
patients in the 0.6-0.9 range in both registries. Reassuringly these studies 
demonstrated a close categorisation match between iFR and FFR. However, given 
the inherent variability of FFR in this range, in the small proportion of patients where 
there is categorisation mismatch CLARIFY used HSR to determine which index (iFR 
or FFR) is more indicative of ischemia. 
 
By indexing the trans-stenotic pressure gradient by flow velocity, HSR, similar to the 
indexes used by Logan has been demonstrated to provide a more epicardial specific 
assessment of coronary stenosis with the ability to differentiate between the 30% of 
patients where FFR and CFR are discordant.  Importantly, it has been demonstrated 
to be more reflective of ischemia than FFR (20, 22).  As an invasive index that 
circumvents the limitation of pressure only indices it was deemed the most 
appropriate arbiter to determine, when FFR and iFR disagree, which was most likely 
to represent the true physiological significance of the stenosis at the level of the 
specific artery.  
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6.6 What does the community think? 
The publication of the findings in this thesis has been met with much debate in the 
community. Other groups, including that of Gould, have compared iFR to FFR and 
alternative invasive and non invasive indices. Apart from a notable exception (61) the 
results have been remarkably consistent. So far iFR and FFR have been compared 
to an independent arbiter of ischaemia in over 500 lesions. Each study has 
demonstrated no difference between the two, arguably with a signal suggesting that 
the resting index may be more accurate.  
 
On the basis of the studies so far iFR has been adopted into clinical practice in over 
300 centres worldwide (Figure 6.1). The natural progression from this point is the 
comparision of iFR guided revascularisation to FFR guided resvascularisation in the 
context of a large blinded randomised trial; using the hard end points of death, 
myocardial infarction and revascularisation as end points. Such a trial is currently 
being performed.  
 
More interestingly and separate to the discussion regarding the accuracy of iFR as 
an index of ischaemia these series of studies have lead the community to re-evaluate 
the broader issue of how new indices of ischaemia should be validated and ask the 
more philosophical question of ‘what is ischaemia?’. 
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7. 0 Conclusion 
Combined analysis of pressure and flow velocity using wave-intensity analysis 
demonstrates a period in the cardiac cycle during which intra-coronary 
haemodynamics are naturally most reflective of the upstream fluid dynamics of the 
stenosis. This diastolic wave-free period provides a more consistent reduction in 
microvascular resistance than that possible with adenosine whilst also lowering 
microvascular resistance sufficiently to discriminate between stenoses. As a result it 
satisfies the requisite conditions for a pressure only assessment of stenosis severity 
without requiring potent vasodilators. The instantaneous wave free ratio is a 
vasodilator free index of stenosis severity that is calculated during this period. It 
appears to have equivalent diagnostic agreement to traditional vasodilator based 
indices and warrants further investigation into its clinical potential with outcome 
studies.     
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  Figure 6.1 : From
 bench to bed-side, the use of iFR
 to guide clinical decision m
aking during a live case 
at EuroPC
R
 2014  
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You are being invited to take part in a research study.  Before you decide, it is important for 
you to understand why the research is being done and what it will involve.  Please take time 
to read the following information carefully and discuss it with others if you wish.  Please ask 
us if there is anything that is not clear or if you would like more information.  Thank you for 
reading this. 
 
What is the purpose of the study? 
You are suffering from chest pain or shortness of breath on exertion. This may be due to a 
narrowing of one of your heart arteries. In order to determine if this is the case we sometimes 
use a test to measure the pressure across the narrowing. This is called Fractional Flow 
Reserve (FFR). In some patients it may not be that accurate. We have developed an 
alternative way of assessing blood flow in the heart arteries. The results from this study may 
lead to a new way of assessing how severe the narrowing in your artery is and therefore may 
affect how we treat patients with your condition in the future.  
 
Why have I been chosen? 
You have been chosen because you are scheduled to have an angioplasty, are not asthmatic 
and do not have any metal implants.  As a normal part of this procedure, a small tube will be 
inserted into the main artery in the groin.   This means that at the time of your procedure, we 
can use this tube to pass our wires into your heart arteries and safely take measurements in 
your heart’s blood vessels.   
 
Do I have to take part? 
No. Your decision whether to participate in this study is entirely voluntary. You have the right 
to refuse as well as to withdraw your participation at any time (even if you agree today) 
without giving a reason. If you decide not to participate or to withdraw, it will not affect the 
quality of your care or treatment, nor the relationship you have with your doctor and nursing 
team. 
 
What will happen to me if I take part? 
You will undergo the routine investigations required prior to angiography which includes an 
ultrasound of the heart (Echocardiogram). After we have performed the procedure and 
obtained all the necessary information to assess your symptoms we will make our 
measurements. We will enter the artery at the top of your leg via the same tube that is 
required for the angiogram. Wires and a balloon will then be passed into the heart arteries 
and measurements taken with an adenosine infusion. This will require a small tube to be 
placed at the top of the leg next to the first tube. Local anaesthetic will be used and this 
should not cause any discomfort. In total the process will add 10 minutes to the procedure. 
The measurements will not prolong your recovery from the procedure. At the end of the 
procedure the wires will be removed. 
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You will then be invited to return to hospital for an MRI scan. This is a non invasive test that 
lasts for 30 minutes where we take pictures of your heart.  
 
You will then be followed up by the clinical team as normal. 
 
What are the possible side effects, risks and disadvantages of taking part? 
We do not expect you to experience any significant side effects as a result of participating in 
this study.  
 
During the measurements we will administer a medication called adenosine. This is routinely 
used every day in the cardiac catheter laboratory and maybe used in the clinical stages of 
your procedure.  The risk of using adenosine is very low, but, in some patients it may cause a 
short lived chest discomfort which usually disappears within 3-5 seconds of stopping the drug. 
In order to administer the adenosine we will place a second tube at the top of the leg using 
local anaesthetic which should not cause any discomfort. In order to administer the adenosine 
we will place a second tube at the top of the leg using local anaesthetic which should not 
cause any discomfort. The measurements extend the length of the procedure by 10 minutes. 
 
There is a very low risk (less than 1 in 1000) that the wire used to make the measurements 
will cause any damage to your blood vessels. The risk of death, heart attack or stroke is the 
same as your routine angiogram. This risk is minimised as the measurements are performed 
by an experienced senior Consultant Cardiologist. We will place the wires under x-ray 
guidance; the extra dose has not been associated with any side effects. This has been 
checked by a radiation expert.  
 
As part of the study you will be invited to have a MRI scan of your heart. This involves lying 
on a table and passing through a tube during which time we take pictures of the heart. There 
are several reasons why you may not be suitable for a MRI. In particular, patients who have 
implanted medical devices (e.g. pacemakers or defibrillators, cochlear implants, cerebral 
aneurysm clips), or who may have iron fragments in their eyes, are not suitable for MRI 
investigation. Orthopaedic pins, mediastinal clips, coronary stents, and the majority of artificial 
heart valves are safe to scan. There are no known risks from undergoing MRI during 
pregnancy. A small number of people suffer from claustrophobia (<5%). We will inject a small 
amount of contrast during the study into a small arm vein and there is a small risk of an 
allergic reaction, although this risk is very low. 
 
What are the possible benefits of taking part? 
You will not directly benefit from this study, but the information we gain will give us a much 
better understanding of how blood flow to the heart muscle is affected in your condition and 
may help develop a new way of assessing if the narrowing in your heart artery is causing your 
chest pain.  
 
What if something goes wrong? 
Imperial College London holds insurance policies which apply to this study.  If you experience 
serious and enduring harm or injury as a result of taking part in this study, you may be eligible to 
claim compensation without having to prove that Imperial College is at fault.  This does not 
affect your legal rights to seek compensation.  
  
If you are harmed due to someone’s negligence, then you may have grounds for a legal 
action.  Regardless of this, if you wish to complain, or have any concerns about any aspect of 
the way you have been treated during the course of this study then you should immediately 
inform the Investigator (Dr Justin Davies 020 7594 1264). The normal National Health Service 
complaint complaints mechanisms are also available to you.  If you are still not satisfied with the 
response, you may contact the Imperial AHSC Joint Research Office. 
 
Will my taking part in this study be kept confidential? 
If you agree to take part, data collected about you will be entered onto a computer. However, 
all data entered will be in an anonymous format and any information obtained from this 
investigation that can be identified will remain confidential. Relevant sections of your medical 
notes & data collected during the study may be looked at by individuals from Imperial College, 
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from regulatory authorities or from Imperial NHS trust, where it is relevant to you taking part in 
this research.  We will ask for your permission for these individuals to have access to your 
records. Your GP will be informed that you are participating in this study. 
 
What will happen to the results of the research study? 
Scientific data from this study may be presented at meetings and published so that the 
information can be used to help others, but your participation in the study will not be made 
known and will be kept strictly confidential. If you wish, we will give you a summary of the 
results. 
 
Who has reviewed the study? 
This study has been reviewed and given a favourable ethical opinion by the Outer London 
Research Ethics Committee. 
 
If you have any further questions please do not hesitate to contact:  
Dr Sayan Sen on 0207 594 1264 or Dr Justin Davies on 0207 594 1264  
 
Thank you for taking the time to consider participating in this study 
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CONSENT FORM 
(Patients scheduled for pressure-flow wire measurements during coronary angioplasty) 
Assessment of Coronary Stenosis: development and application of separated 
pressure Fractional Flow Reserve 
Chief Investigator:  Dr Justin Davies, Dept of Cardiology, ICCH St Mary’s NHS Trust 
 
  
 
1.          I have read the Patient Information Sheet (Version 5.0 Date 
18/12/2009) for patients scheduled for Assessment of 
Coronary Stenosis: development and application of 
separated pressure Fractional Flow Reserve 
 
  
2. I have received enough information about this study, had the 
opportunity to ask questions and I am satisfied with the answers 
to my questions. 
 
3. I have spoken to Dr...............………………………… 
 
4. I understand that I am free to withdraw from the study at any 
time without giving a reason and without affecting my future 
care. 
 
5.          I understand that relevant sections of any of my medical notes 
and data collected during the study may be looked at by 
responsible individuals from Imperial College, from regulatory 
authorities or from the NHS Trust. I give permission for these 
individuals to access my records. 
 
6.          I agree to take part in this research study. 
 
7.          I agree to my GP being informed about my participation in this 
research study. 
 
Signature............................................…………………………… 
Name (block capitals)................................………….…………... 
 
Signature of Study Investigator.................................…………… 
Name (block capitals)................................……………………… 
Please initial as 
applicable 
 
Yes …… No…… 
 
 
 
 
Yes …… No…… 
 
 
 
Yes …… No…… 
 
Yes …… No…… 
 
 
 
 
Yes …… No…… 
 
Yes …… No…… 
 
Yes …… No…… 
 
 
Date................ 
 
 
Date................ 
 
  
 
 
